The Cotransplantation of Olfactory Ensheathing Cells with Bone Marrow Mesenchymal Stem Cells	1
The Cotransplantation	1
Olfactory Ensheathing Cells with Bone Marrow Mesenchymal Stem Cells	26
Olfactory Ensheathing Cells	26
Bone Marrow Mesenchymal Stem Cells	59
Antiapoptotic Effects in Adult Rats	101
Antiapoptotic Effects	101
Adult Rats	126
Spinal Cord Injury ShifengWu ,1 Guanqun Cui ,2 Hua Shao ,3 Zhongjun Du ,3 Jack C. Ng ,4 and Cheng Peng4 The mechanisms behind the repairing effects of the cotransplantation of olfactory ensheathing cells -LRB- OECs -RRB- with bone marrow mesenchymal stromal cells -LRB- BMSCs -RRB- have not been fully understood.Therefore	143
Spinal Cord Injury ShifengWu ,1 Guanqun Cui ,2 Hua Shao ,3 Zhongjun Du ,3 Jack C. Ng ,4	143
Cheng Peng4 The mechanisms behind the repairing effects of the cotransplantation of olfactory ensheathing cells -LRB- OECs -RRB- with bone marrow mesenchymal stromal cells -LRB- BMSCs -RRB- have not been fully understood.Therefore	231
Cheng Peng4 The mechanisms	231
the repairing effects of the cotransplantation of olfactory ensheathing cells -LRB- OECs -RRB- with bone marrow mesenchymal stromal cells -LRB- BMSCs -RRB- have not been fully understood.Therefore	266
effects of the cotransplantation of olfactory ensheathing cells -LRB- OECs -RRB-	280
effects	280
the cotransplantation of olfactory ensheathing cells -LRB- OECs -RRB-	291
the cotransplantation	291
olfactory ensheathing cells -LRB- OECs -RRB-	316
olfactory ensheathing cells	316
OECs	345
bone marrow mesenchymal stromal cells -LRB- BMSCs -RRB- have not been fully	356
bone marrow	356
mesenchymal stromal cells -LRB- BMSCs -RRB-	368
mesenchymal stromal cells	368
BMSCs	395
we	444
the effects of the cotransplantation of OECs with BMSCs on antiapoptotic effects	460
the effects	460
the cotransplantation of OECs with BMSCs on antiapoptotic effects	475
the cotransplantation	475
OECs with BMSCs on antiapoptotic effects	500
OECs	500
BMSCs on antiapoptotic effects	510
BMSCs	510
antiapoptotic effects	519
adult rats for which the models of SCI are induced	544
adult rats	544
the models of SCI	565
the models	565
SCI	579
We	596
the changes	608
body weight , histopathological changes , apoptosis , and the expressions of apoptosis-related proteins	623
body weight	623
histopathological changes	636
apoptosis	663
the expressions of apoptosis-related proteins	678
the expressions	678
apoptosis-related proteins	697
14 days and 28 days	730
14 days	730
28 days	742
transplantation	756
We	773
animal	790
locomotion using BBB test	797
locomotion	797
BBB test	814
We	824
treatment with OECs and BMSCs	838
treatment	838
OECs and BMSCs	853
a remissive effect on behavioral outcome	872
a remissive effect	872
behavioral outcome	894
histopathological changes	917
SCI	951
we	969
the significant antiapoptotic effect	981
cotransplant treated group	1021
addition	1052
cotransplantation of OECs with BMSCs	1062
cotransplantation	1062
OECs with BMSCs	1083
OECs	1083
BMSCs	1093
more significant repairing effect than that of OECs or BMSCs alone	1117
more significant	1117
effect	1144
that of OECs or BMSCs	1156
that	1156
OECs or BMSCs	1164
the recovery of hind limb	1198
the recovery	1198
hind limb	1214
antiapoptotic effect of OECs and BMSCs	1244
antiapoptotic effect	1244
OECs and BMSCs	1268
the apoptotic pathways	1306
our data	1339
the cotransplantation of OECs with BMSCs	1358
the cotransplantation	1358
OECs with BMSCs	1383
OECs	1383
BMSCs	1393
promise for a potential cure after SCI	1405
promise	1405
a potential cure after SCI	1417
a potential cure	1417
SCI	1440
the ability to incorporate into the spinal cord	1452
the spinal cord	1484
Introduction Spinal cord injury -LRB- SCI -RRB-	1505
Introduction Spinal cord injury	1505
Introduction	1505
Spinal cord injury	1518
SCI	1538
a destructive neurologic injury resulting in functional deficits due to the loss of spinal cord neurons and axons	1546
a destructive neurologic injury	1546
functional deficits due to the loss of spinal cord neurons and axons	1591
functional deficits	1591
the loss of spinal cord neurons and axons	1618
the loss	1618
spinal cord neurons and axons	1630
Extensive attempts	1661
repair and recovery cells	1706
the injury for potential treatments of SCI	1737
the injury	1737
potential treatments of SCI	1752
potential treatments	1752
SCI	1776
the use of stem cells as transplant tissue	1792
the use	1792
stem cells as transplant tissue	1803
stem cells	1803
transplant tissue	1817
particular promise	1841
they	1866
endogenous destroyed cells through facilitating cell regeneration	1883
endogenous	1883
cells	1904
cell regeneration	1931
neurons -LSB- 1 -RSB-	1972
neurons	1972
1 -RSB-	1981
Cellbased therapies	1985
beneficial effects	2023
different types of cells in preclinical models	2048
different types	2048
cells in preclinical models	2067
cells	2067
preclinical models	2076
-LSB- 2 , 3 -RSB-	2095
Olfactory ensheathing cells -LRB- OECs -RRB- and bone marrow mesenchymal stromal stem cells -LRB- BMSCs -RRB-	2103
Olfactory ensheathing cells -LRB- OECs -RRB-	2103
Olfactory ensheathing cells	2103
OECs	2132
bone marrow mesenchymal stromal stem cells -LRB- BMSCs -RRB-	2142
bone marrow mesenchymal stromal stem cells	2142
BMSCs	2186
two of the most studied cells for SCI repair in experimental models and showed good perspectives for clinical applications of cell therapy	2197
two	2197
the most studied cells for SCI repair in experimental models and showed good perspectives for clinical applications of cell therapy	2204
the most	2204
cells for SCI repair	2221
cells	2221
SCI repair	2231
experimental models	2245
good perspectives	2276
clinical applications of cell therapy	2298
clinical applications	2298
cell therapy	2323
OECs	2337
unique glial cells found in the olfactory systems that support olfactory neurogenesis and the retargeting across the peripheral nervous system/the central nervous system boundary in the olfactory system	2346
unique glial cells	2346
the olfactory systems that support olfactory neurogenesis and the retargeting across the peripheral nervous system/the central nervous system boundary in the olfactory system	2374
the olfactory systems	2374
olfactory neurogenesis and the retargeting across the peripheral nervous system/the	2409
olfactory neurogenesis	2409
the retargeting across the peripheral nervous system/the	2436
the retargeting	2436
the peripheral nervous system/the	2459
central nervous system boundary in the olfactory system	2493
central nervous system boundary	2493
the olfactory system	2528
These cells	2550
tissue sparing and neuroprotection , enhance outgrowth of both intact and lesioned axons , activate angiogenesis , and remyelinate axons after a range of demyelinating insults -LSB- 4 -RSB-	2584
tissue sparing and neuroprotection	2584
outgrowth	2628
both intact and lesioned axons	2641
angiogenesis	2682
remyelinate axons after a range of demyelinating insults -LSB- 4 -RSB-	2700
remyelinate axons	2700
a range of demyelinating insults -LSB- 4 -RSB-	2724
a range	2724
demyelinating insults -LSB- 4 -RSB-	2735
demyelinating insults	2735
4 -RSB-	2758
Recent studies	2762
OEC	2793
the differentiation of stem cells	2809
the differentiation	2809
stem cells	2832
the olfactory system	2848
the olfactory neurons	2876
-LSB- 5 , 6 -RSB-	2898
Acute transplantation of OECs into partial or complete spinal cord lesions	2906
Acute transplantation	2906
OECs into partial or complete spinal cord lesions	2931
OECs	2931
partial or complete spinal cord lesions	2941
the volume of injured tissue	3006
the volume	3006
injured tissue	3020
axonal regeneration	3044
some functions -LSB- 7 -RSB-	3077
some functions	3077
7 -RSB-	3093
The proposed mechanisms of action of grafted OECs	3097
The proposed mechanisms	3097
action of grafted OECs	3124
action	3124
grafted OECs	3134
their interaction	3155
astrocytes -LSB- 8 -RSB- , modulation of the early neuroinflammatory response -LSB- 9 -RSB- , remyelination and enhancement of axonal regeneration -LSB- 10 -RSB- , and promotion of angiogenesis	3178
astrocytes	3178
8 -RSB- , modulation of the early neuroinflammatory response -LSB- 9 -RSB- , remyelination and enhancement of axonal regeneration -LSB- 10 -RSB- , and promotion of angiogenesis	3190
8 -RSB-	3190
modulation of the early neuroinflammatory response -LSB- 9 -RSB- , remyelination and enhancement of axonal regeneration -LSB- 10 -RSB- , and promotion of angiogenesis	3194
modulation	3194
the early neuroinflammatory response -LSB- 9 -RSB- , remyelination and enhancement	3208
the early neuroinflammatory response	3208
9 -RSB- , remyelination and enhancement	3246
axonal regeneration -LSB- 10 -RSB- , and promotion of angiogenesis	3283
axonal regeneration	3283
10 -RSB- , and promotion of angiogenesis	3304
10 -RSB-	3304
promotion of angiogenesis	3313
promotion	3313
angiogenesis	3326
progenitor OECs	3351
one of the most promising cell sources	3389
one	3389
the most promising cell sources	3396
SCI therapy	3432
BMSCs	3445
functional recovery	3489
-LSB- 11 , 12 -RSB-	3509
intrathecal injection or intravenous perfusion	3522
intrathecal injection	3522
intravenous perfusion	3547
The mechanisms underlying the beneficial effects of BMSCs transplants	3570
The mechanisms	3570
the beneficial effects of BMSCs transplants	3596
the beneficial effects	3596
BMSCs transplants	3622
neuroprotection	3652
the expression of neuroprotective molecules in the injured tissues -LSB- 12 -RSB- , contribution to a permissive environment for axonal regeneration and neural tissue reconstruction -LSB- 13 -RSB- , acceleration of the tissue repair process -LSB- 9 -RSB- , and modulation of the neuroinflammatory response	3693
the expression of neuroprotective molecules in the injured tissues -LSB- 12 -RSB-	3693
the expression	3693
neuroprotective molecules in the injured tissues -LSB- 12 -RSB-	3711
neuroprotective molecules	3711
the injured tissues -LSB- 12 -RSB-	3740
the injured tissues	3740
12 -RSB-	3761
contribution to a permissive environment for axonal regeneration and neural tissue reconstruction -LSB- 13 -RSB-	3766
contribution	3766
a permissive environment for axonal regeneration and neural tissue reconstruction -LSB- 13 -RSB-	3782
a permissive environment	3782
axonal regeneration and neural tissue reconstruction -LSB- 13 -RSB-	3811
axonal regeneration and neural tissue reconstruction	3811
13 -RSB-	3865
acceleration of the tissue repair process -LSB- 9 -RSB-	3870
acceleration	3870
the tissue repair process -LSB- 9 -RSB-	3886
the tissue repair process	3886
9 -RSB-	3913
modulation of the neuroinflammatory response	3921
modulation	3921
the neuroinflammatory response	3935
recent years	3970
much attention	3984
secondary cord injury	4016
this	4044
therapeutic intervention	4079
Apoptosis and inflammatory responses and some other neurological toxicity events	4105
Apoptosis and inflammatory responses	4105
some other neurological toxicity events	4146
the secondary injury	4198
primary insult in the spinal cord -LSB- 1 -RSB-	4225
primary insult	4225
the spinal cord -LSB- 1 -RSB-	4243
the spinal cord	4243
1 -RSB-	4260
Apoptosis	4263
both a receptor-dependent extrinsic pathway and mitochondria	4282
a receptor-dependent extrinsic pathway	4287
mitochondria	4330
spinal cord injuries , which are activated in spinal cord injuries -LSB- 14 -RSB-	4357
spinal cord injuries	4357
spinal cord injuries -LSB- 14 -RSB-	4402
spinal cord injuries	4402
14 -RSB-	4424
Several studies	4429
the apoptotic role of caspases	4461
the apoptotic role	4461
caspases	4483
the injured spinal cord -LSB- 15	4495
the injured spinal cord	4495
15	4520
17 -RSB-	4523
Activation of Caspase-3 and Caspase-8 and apoptosis	4528
Activation	4528
Caspase-3 and Caspase-8 and apoptosis	4542
a temporally similar fashion after SCI -LSB- 18 -RSB-	4589
a temporally similar fashion	4589
SCI -LSB- 18 -RSB-	4624
SCI -LSB-	4624
Many other genes	4634
apoptosis , such as the antiapoptosis gene Bcl-2 and apoptosisinducer Bax	4667
apoptosis	4667
the antiapoptosis gene Bcl-2 and apoptosisinducer Bax	4686
a study using Bcl-2 overexpressed transgenic mice	4751
a study	4751
Bcl-2 overexpressed transgenic mice	4765
Bcl-2	4765
transgenic mice	4785
overexpression of Bcl - 2	4819
overexpression	4819
Bcl - 2	4837
Bcl	4837
2	4842
neuronal apoptosis	4854
spinal cord injury	4879
recovery of neurological function	4911
recovery	4911
neurological function	4923
19 -RSB-	4946
contrast	4954
Bax , a cytosolic protein in normal living cells ,	4964
Bax	4964
a cytosolic protein in normal living cells	4969
a cytosolic protein	4969
normal living cells	4992
apoptosis	5024
tomitochondria	5059
an early stage of the apoptotic process	5077
an early stage	5077
the apoptotic process	5095
Kotipatruni et al. -LSB- 20 -RSB-	5118
Kotipatruni et al. -LSB-	5118
upregulation of Bax and downregulation of Bcl-2	5149
upregulation	5149
Bax and downregulation	5165
Bcl-2	5191
rat spinal cords	5200
SCI.These	5223
the involvement of a mitochondrial-mediated apoptotic pathway	5251
the involvement	5251
a mitochondrial-mediated apoptotic pathway	5270
SCI	5319
the natural capacity of the central nervous system to recover from injury	5330
the natural capacity	5330
the central nervous system	5354
injury	5397
current SCI research	5416
the use of regenerative potential of OECs or BMSCs	5448
the use	5448
regenerative potential of OECs or BMSCs	5459
regenerative potential	5459
OECs or BMSCs	5485
the damaged neurons and oligodendrocytes	5510
neuronal plasticity	5563
These studies	5584
the reduction of neural degeneration and certain functional recovery	5605
the reduction	5605
neural degeneration and certain functional recovery	5622
neural degeneration	5622
certain functional recovery	5646
transplantation of either OECs or BMSCs	5677
transplantation	5677
either OECs or BMSCs	5696
A precious study	5718
the antiapoptotic effects of transplantation of BMSCs	5742
the antiapoptotic effects	5742
transplantation of BMSCs	5771
transplantation	5771
BMSCs	5790
spinal cord injury -LSB- 21 -RSB-	5802
spinal cord injury	5802
21 -RSB-	5822
OECs and BMSCs	5837
damaged organs or tissues , where they differentiate into myocardiocytes and neurons	5885
damaged organs or tissues	5885
they	5918
myocardiocytes and neurons	5942
cell lineages	5969
22 -RSB-	5984
we	6000
cotransplantation of OECs with BMSCs	6021
cotransplantation	6021
OECs with BMSCs	6042
OECs	6042
BMSCs	6052
stronger effects	6067
neural degeneration induced by SCI	6087
neural degeneration	6087
SCI	6118
We	6123
the improved neurological functions by cotransplantation of OECs with BMSCs	6152
the improved neurological functions	6152
cotransplantation of OECs with BMSCs	6191
cotransplantation	6191
OECs with BMSCs	6212
OECs	6212
BMSCs	6222
throughthe regulationofBax,Bcl-2 , Caspase-9 , andCaspase-3	6244
throughthe regulationofBax,Bcl-2	6244
Caspase-9 , andCaspase-3	6277
Caspase-9	6277
andCaspase-3	6287
the hypothesis	6309
we	6325
OECs and BMSCs	6341
cotransplantation of OECs	6360
cotransplantation	6360
OECs	6381
BMSCs in rats with SCI	6391
BMSCs	6391
rats with SCI	6400
rats	6400
SCI	6410
behavioral activities and histopathological changes	6428
behavioral activities	6428
histopathological changes	6454
the expression of the protein involved in mitochondria-associated apoptotic pathway	6493
the expression	6493
the protein involved in mitochondria-associated apoptotic pathway	6511
the protein	6511
mitochondria-associated apoptotic pathway	6535
Materials and Methods 2.1 .	6582
Materials and Methods 2.1	6582
Materials	6582
Methods 2.1	6596
Experimental Animals and Experimental Design .	6609
Experimental Animals and Experimental Design	6609
Experimental Animals	6609
Experimental Design	6634
Adult female Wistar rats weighting 250 -- 300 g were purchased from the Department of Experimental Animals , Shandong University , China -LRB- the number for certificate of animals is SCXK -LRB- Lu -RRB- 2013-0009 -RRB- , and maintained under standard housing conditions -LRB- temperature : 18 -- 24 ∘ C ; relative humidity : 45 % ; light and dark cycle : 12 h : 12 h -RRB- .	6655
Adult female Wistar rats weighting 250	6655
Adult female Wistar rats	6655
weighting 250	6680
300 g were purchased from the Department of Experimental Animals , Shandong University , China -LRB- the number for certificate of animals is SCXK -LRB- Lu -RRB- 2013-0009 -RRB- , and maintained under standard housing conditions -LRB- temperature : 18 -- 24 ∘ C ; relative humidity : 45 % ; light and dark cycle : 12 h : 12 h -RRB-	6694
300 g	6694
the Department of Experimental Animals , Shandong University , China -LRB- the number for certificate of animals is SCXK -LRB- Lu -RRB- 2013-0009 -RRB- ,	6720
the Department of Experimental Animals	6720
the Department	6720
Experimental Animals	6738
Shandong University , China -LRB- the number for certificate of animals is SCXK -LRB- Lu -RRB- 2013-0009 -RRB-	6760
Shandong University	6760
China	6781
the number for certificate of animals	6788
the number	6788
certificate of animals	6803
certificate	6803
animals	6818
SCXK -LRB- Lu -RRB- 2013-0009	6829
SCXK -LRB- Lu -RRB-	6829
SCXK	6829
Lu	6835
2013-0009	6839
standard housing conditions -LRB- temperature : 18 -- 24 ∘ C ; relative humidity : 45 % ; light and dark cycle : 12 h : 12 h -RRB-	6872
standard housing conditions	6872
temperature : 18 -- 24 ∘ C ; relative humidity : 45 % ; light and dark cycle : 12 h : 12 h	6901
temperature	6901
18 -- 24 ∘ C ; relative humidity : 45 % ; light and dark cycle : 12 h : 12 h	6914
18 -- 24 ∘ C	6914
18	6914
24 ∘ C	6917
relative humidity : 45 %	6923
relative humidity	6923
45 %	6942
light and dark cycle	6947
light	6947
dark cycle	6957
12 h : 12 h	6969
12 h	6969
12 h	6976
Food and water	6983
Food	6983
water	6992
ad libitum	7012
All animalswere	7024
the protocols evaluated and approved by the ethical committee of Shandong University School of Medicine	7061
the protocols	7061
the ethical committee of Shandong University School of Medicine	7101
the ethical committee	7101
Shandong University School of Medicine	7126
Shandong University School	7126
Medicine	7156
60 adult female Wistar rats	7166
5 groups which included -LRB- 1 -RRB- control group -LRB- = 12 -RRB- in which rats are only treated with laminectomy without SCI for comparison ; -LRB- 2 -RRB- sham group -LRB- = 12 -RRB- in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection ; -LRB- 4 -RRB- BMSCs treated group -LRB- = 12 -RRB- which received 3 × 105 BMSCs by intraspinal injection ; -LRB- 5 -RRB- cotransplant treated group -LRB- = 12 -RRB- which received 3 × 105 OECs and BMSCs in the same way	7221
5 groups	7221
-LRB- 1 -RRB- control group -LRB- = 12 -RRB- in which rats are only treated with laminectomy without SCI for comparison ; -LRB- 2 -RRB- sham group -LRB- = 12 -RRB- in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection ; -LRB- 4 -RRB- BMSCs treated group -LRB- = 12 -RRB- which received 3 × 105 BMSCs by intraspinal injection ; -LRB- 5 -RRB- cotransplant treated group -LRB- = 12 -RRB- which received 3 × 105 OECs and BMSCs in the same way	7245
-LRB- 1 -RRB- control group -LRB- = 12 -RRB- in which rats are only treated with laminectomy without SCI for comparison	7245
control	7249
group -LRB- = 12 -RRB- in which rats are only treated with laminectomy	7257
group	7257
= 12	7267
rats	7282
laminectomy	7309
SCI	7329
comparison	7337
-LRB- 2 -RRB- sham group -LRB- = 12 -RRB- in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	7349
sham	7353
group -LRB- = 12 -RRB-	7358
group	7358
= 12	7368
in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	7374
DMEM culture medium	7383
intraspinal injection	7423
-LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	7446
OECs	7449
group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	7462
group	7462
= 12	7472
3 × 105 OECs by intraspinal injection	7493
3 × 105 OECs	7493
intraspinal injection	7509
-LRB- 4 -RRB- BMSCs treated group -LRB- = 12 -RRB- which received 3 × 105 BMSCs by intraspinal injection ; -LRB- 5 -RRB- cotransplant treated group -LRB- = 12 -RRB- which received 3 × 105 OECs	7532
BMSCs	7536
group -LRB- = 12 -RRB- which received 3 × 105 BMSCs by intraspinal injection ; -LRB- 5 -RRB- cotransplant treated group -LRB- = 12 -RRB- which received 3 × 105 OECs	7550
group	7550
= 12	7560
3 × 105 BMSCs	7581
3 ×	7581
105 BMSCs	7585
intraspinal injection	7598
5	7622
cotransplant treated group -LRB- = 12 -RRB- which received 3 × 105 OECs	7625
cotransplant treated group	7625
= 12	7656
3 ×	7677
105 OECs	7681
BMSCs in the same way	7694
BMSCs	7694
the same way	7703
We	7717
12 animals	7737
each group	7751
two groups -LRB- 14-day posttransplantation group and 28-day posttransplantation group -RRB-	7767
two groups	7767
14-day posttransplantation group and 28-day posttransplantation group	7779
14-day posttransplantation group	7779
28-day posttransplantation group	7816
14 and 28 days after transplantation	7854
14 and 28 days	7854
transplantation	7875
the animals -LRB- = 6 -RRB- from each group	7892
the animals -LRB- = 6 -RRB-	7892
the animals	7892
= 6	7908
each group	7918
different parameters	7949
Figure 1	7982
2.2	7992
Spinal Cord Injury Model .	7997
Spinal Cord	7997
Injury Model	8009
A standard spinal cord contusion	8023
the New York University -LRB- NYU -RRB- weight drop device as detailed previously -LSB- 16 -RSB-	8074
the New York University -LRB- NYU -RRB- weight drop device	8074
New York University -LRB- NYU -RRB-	8078
New York University	8078
NYU	8099
detailed previously -LSB- 16 -RSB-	8126
16	8147
the adult female rats	8161
an operating table covered with a warming blanket	8221
an operating table	8221
a warming blanket	8253
the midthoracic region	8286
Betadine	8327
an incision	8337
the midthoracic region	8363
Laminectomy on each rat	8387
Laminectomy	8387
each rat	8402
the T9 -- T11 under chloral hydrate anesthesia	8428
the T9	8428
T11 under chloral hydrate anesthesia	8435
T11	8435
chloral hydrate anesthesia	8445
The impact rod of the impactor of 10 g	8473
The impact rod	8473
the impactor of 10 g	8491
the impactor	8491
10 g	8507
T10	8531
a height of 50mmto induce a consistent partial SCI	8552
a height	8552
50mmto induce a consistent partial SCI	8564
50mmto	8564
a consistent partial SCI	8578
Analgesia	8604
buprenorphine -LRB- 0.1 mg/kg -RRB- for 2 days	8633
buprenorphine -LRB- 0.1 mg/kg -RRB-	8633
buprenorphine	8633
0.1 mg/kg	8648
2 days	8662
surgery	8675
Gentamicin -LRB- 0.8 mg/100 g , ip -RRB- and Ringer 's solution to avoid dehydration -LRB- 2mL , ip , after surgery -RRB-	8684
Gentamicin -LRB- 0.8 mg/100 g , ip -RRB-	8684
Gentamicin	8684
0.8 mg/100 g	8696
ip	8709
Ringer 's solution to avoid dehydration -LRB- 2mL , ip , after surgery -RRB-	8717
Ringer 's solution to avoid dehydration	8717
Ringer 's	8717
dehydration	8744
2mL , ip	8757
2mL	8757
ip	8762
surgery	8772
urinary tract infection for 3 -- 7 days	8811
urinary tract infection for 3	8811
urinary tract infection	8811
3	8839
7 days	8841
Passive mobilization of the hind legs for 15 minutes	8849
Passive mobilization	8849
the hind legs for 15 minutes	8873
the hind legs	8873
15 minutes	8891
every day for a week	8917
every day	8917
a week	8931
surgery	8944
Postoperative care	8953
manual bladder expression	8981
2 times	9007
a day	9015
reflex bladder emptying	9027
reflex bladder	9027
2.3	9068
Culture and Identification of Stem Cells .	9073
Culture and Identification	9073
Stem Cells	9103
OECs from olfactory bulbs of healthy female adult Sprague Dawley rats -LRB- = 6 -RRB- weighting 220 -- 300 g were cultured as	9115
OECs	9115
olfactory bulbs of healthy female adult Sprague Dawley rats -LRB- = 6 -RRB-	9125
olfactory bulbs	9125
healthy female adult Sprague Dawley rats -LRB- = 6 -RRB-	9144
healthy female adult Sprague Dawley rats	9144
= 6	9189
weighting 220	9194
300 g	9208
slight modifications	9256
-LSB- 23 , 24 -RSB-	9277
brief	9290
the Sprague Dawley ratswere	9297
3 % pentobarbital sodiumanesthetic overdose	9339
0.5 % iodophor solution	9401
5 minutes	9434
rats	9445
the super-clean bench	9468
The cranial cavity	9491
the cranial sagittal suture from the foramen magnum	9524
the cranial sagittal suture	9524
the foramen magnum	9557
Olfactory bulbs	9577
2 times	9618
PBS	9631
small pieces	9646
sterile ophthalmic scissors	9664
4 ∘ C DMEM -LRB- with penicillin/streptomycin , 100 / mL -RRB- -LRB- GIBCO , USA -RRB-	9717
4 ∘ C DMEM -LRB- with penicillin/streptomycin , 100 / mL -RRB-	9717
4 ∘ C DMEM	9717
penicillin/streptomycin , 100 / mL	9732
penicillin/streptomycin	9732
100 / mL	9757
100	9757
mL	9764
GIBCO	9769
USA	9776
centrifuge	9798
800 r.p.m -LRB- Thermo Fisher , USA -RRB- , the tissue pieceswere digestedwith 0.125 % pancreatin -	9809
800 r.p.m	9809
Thermo Fisher	9820
USA	9835
the tissue pieceswere digestedwith 0.125 % pancreatin	9841
EDTA	9894
37 ∘ C for 30 minutes	9902
37 ∘ C	9902
30 minutes	9911
The cell suspension with the cells in 104/mL	9923
The cell suspension	9923
the cells in 104/mL	9948
the cells	9948
104/mL	9961
CO2 incubator -LRB- Thermo Fisher Labserv CO-150 , USA -RRB-	9998
CO2 incubator	9998
Thermo Fisher Labserv CO-150	10013
USA	10043
DMEM	10072
OECswere identifiedby immunohistochemistrywithp75 antibody	10103
Cells at 60 % confluency	10163
Cells	10163
60 % confluency	10172
3 times	10199
PBS followed by incubation of 4 % paraformaldehyde for 20 minutes at room temperature	10212
PBS	10212
incubation of 4 % paraformaldehyde for 20 minutes at room temperature	10228
incubation	10228
4 % paraformaldehyde for 20 minutes at room temperature	10242
4 % paraformaldehyde	10242
20 minutes at room temperature	10266
20 minutes	10266
room temperature	10280
5 % BSA for 30 minutes	10323
5 % BSA	10323
30 minutes	10334
the cells	10346
p75 antibody -LRB- 1 : 100 -RRB- -LRB- Sigma , USA -RRB-	10376
p75 antibody -LRB- 1 : 100 -RRB-	10376
p75 antibody	10376
1 : 100	10390
1	10390
100	10394
Sigma	10400
USA	10407
4 ∘ C overnight	10415
4 ∘	10415
C overnight	10417
The cells on slides	10430
The cells	10430
slides	10443
microscope	10468
fluorescencemicroscope -LRB- OLYMPUS , Japan -RRB-	10496
fluorescencemicroscope	10496
OLYMPUS	10520
Japan	10529
incubation with secondary at antibody -LRB- 1 : 200 -RRB- -LRB- Sigma , USA -RRB- for 40 minutes at 37 ∘ C. BMSCs	10542
incubation	10542
secondary at antibody -LRB- 1 : 200 -RRB- -LRB- Sigma , USA -RRB- for 40 minutes at 37 ∘ C. BMSCs	10558
secondary	10558
antibody -LRB- 1 : 200 -RRB- -LRB- Sigma , USA -RRB-	10571
antibody	10571
1 : 200	10581
1	10581
200	10585
Sigma	10591
USA	10598
40 minutes at 37 ∘ C. BMSCs	10607
40 minutes	10607
37 ∘ C. BMSCs	10621
the repeated adherent culture method as described by Qian et al. -LSB- 25 -RSB-	10666
the repeated adherent culture method	10666
Qian et al. -LSB- 25 -RSB-	10719
Qian et al. -LSB-	10719
Bone marrow	10737
sterile conditions from 8 - week-old female healthy Sprague Dawley rats -LRB- = 6 -RRB- weighting 250 -- 300 g. Briefly , after being sacrificed by anesthetic overdose	10765
sterile conditions from 8 - week-old female healthy Sprague Dawley rats -LRB- = 6 -RRB- weighting 250 -- 300 g. Briefly	10765
sterile conditions from 8	10765
sterile conditions	10765
8	10789
week-old female healthy Sprague Dawley rats -LRB- = 6 -RRB- weighting 250	10792
week-old female healthy Sprague Dawley rats	10792
= 6	10840
weighting 250	10845
300 g. Briefly	10859
300 g.	10859
anesthetic overdose	10901
rats	10922
tibia and femur	10949
antiseptic conditions	10972
medullar cavitywas	10994
DMEM	11026
single cell suspension which was then washed and incubated in CO2 incubator -LRB- Thermo Fisher Labserv CO-150 , USA -RRB-	11038
single cell suspension	11038
CO2 incubator -LRB- Thermo Fisher Labserv CO-150 , USA -RRB-	11100
CO2 incubator	11100
Thermo Fisher Labserv CO-150	11115
USA	11145
The cells	11151
inverted microscope -LRB- OLYMPUS , Japan -RRB-	11187
inverted microscope	11187
OLYMPUS	11208
Japan	11217
Brdu -LRB- 10 / L -RRB- -LRB- Guangzhou RIBOBIO Co. , Ltd , China -RRB-	11225
Brdu -LRB- 10 / L -RRB-	11225
Brdu	11225
10	11231
L	11238
Guangzhou RIBOBIO Co.	11242
Ltd	11265
China	11270
the culture flasks	11292
incubation for 48	11317
incubation	11317
48	11332
72 h and the cells	11336
72 h	11336
the cells	11345
4 % paraformaldehyde for about 20 minutes	11371
4 % paraformaldehyde	11371
about 20 minutes	11395
The cell slides	11413
1 % Triton X-100 , digested with 2 % HCl and the pepsin for 10 minutes	11453
1 % Triton X-100	11453
2 % HCl and the pepsin for 10 minutes	11484
2 % HCl	11484
the pepsin for 10 minutes	11495
the pepsin	11495
10 minutes	11510
5 % BSA -LRB- GIBCO , USA -RRB-	11539
5 % BSA	11539
GIBCO	11547
USA	11554
30 minutes followed by incubation of Brdu antibody -LRB- Guangzhou RIBOBIO Co. , Ltd. , China -RRB- for 30 minutes	11563
30 minutes	11563
incubation of Brdu antibody -LRB- Guangzhou RIBOBIO Co. , Ltd. , China -RRB- for 30 minutes	11586
incubation	11586
Brdu antibody -LRB- Guangzhou RIBOBIO Co. , Ltd. , China -RRB- for 30 minutes	11600
Brdu antibody -LRB- Guangzhou RIBOBIO Co. , Ltd. , China -RRB-	11600
Brdu antibody	11600
Guangzhou RIBOBIO Co.	11615
Ltd.	11638
China	11644
30 minutes	11655
The slides	11667
90 % glycerol	11696
fluorescence microscope -LRB- OLYMPUS , Japan -RRB-	11728
fluorescence microscope	11728
OLYMPUS	11753
Japan	11762
OECs and BMSCs	11770
they	11805
single cell suspension	11853
The concentration	11877
104/mL	11911
bottles	11922
CO2 incubator	11945
medium	11960
every 3 to 4 days	11980
slides	12004
more than 60 %	12024
identification	12047
steps	12082
Viability of OECs , BMSCs , and coculture cells	12089
Viability	12089
OECs , BMSCs , and coculture cells	12102
WST-8 cell counting kit -LRB- CCK-8 , DOJINDO , Japan -RRB-	12154
WST-8 cell counting kit	12154
CCK-8	12179
DOJINDO	12186
Japan	12195
The assay	12203
the manufacturer 's instruction with slight modifications	12240
the manufacturer 's instruction	12240
the manufacturer 's	12240
slight modifications	12276
cells at 2 × 104/mL	12307
cells	12307
2 × 104/mL	12316
a well of a 96-well plate	12344
a well	12344
a 96-well plate	12354
90 per well	12373
90	12373
different time periods -LRB- 2 , 4 , 6 , 8 , 10 , and 12 days -RRB-	12406
different time periods	12406
2 , 4 , 6 , 8 , 10 , and 12 days	12430
2	12430
4	12433
6	12436
8	12439
10	12442
12 days	12450
the end of each incubation time	12463
the end	12463
each incubation time	12474
the cells	12496
addition of 10 CCK-8 solution in each well followed by incubation for 1 h at 37 ∘ C. Optical density at 450 nm was detected by a microplate reader -LRB- Thermo Fisher , USA -RRB-	12521
addition	12521
10 CCK-8 solution in each well followed by incubation for 1 h at 37 ∘ C. Optical density at 450 nm was detected by a microplate reader -LRB- Thermo Fisher , USA -RRB-	12533
10 CCK-8 solution	12533
each well followed by incubation for 1 h at 37 ∘ C. Optical density at 450 nm was detected by a microplate reader -LRB- Thermo Fisher , USA -RRB-	12558
each	12558
incubation for 1 h	12580
incubation	12580
1 h	12595
37 ∘ C. Optical density at 450 nm was detected by a microplate reader -LRB- Thermo Fisher , USA -RRB-	12602
37 ∘	12602
C. Optical density at 450 nm	12605
C. Optical density	12605
450 nm	12627
a microplate reader -LRB- Thermo Fisher , USA -RRB-	12650
a microplate reader	12650
Thermo Fisher	12671
USA	12686
Each experiment	12692
triplicate	12725
three times	12763
Cell viability	12776
the growth rate with respect	12808
the growth rate	12808
respect	12829
the cell number of the day	12840
the cell number	12840
the day	12859
2.4	12868
Transplantation	12873
The rats	12900
5 groups : -LRB- 1 -RRB- control group -LRB- = 12 -RRB- in which rats were only treated with laminectomy without SCI for comparison ; -LRB- 2 -RRB- sham group -LRB- = 12 -RRB- in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection ; -LRB- 4 -RRB- BMSCs treated group -LRB- = 12 -RRB- which received 3 × 105 BMSCs by intraspinal injection ; 105 OECs and BMSCs in the same way	12936
5 groups : -LRB- 1 -RRB- control group -LRB- = 12 -RRB- in which rats were only treated with laminectomy without SCI for comparison ; -LRB- 2 -RRB- sham group -LRB- = 12 -RRB- in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	12936
5 groups	12936
-LRB- 1 -RRB- control group -LRB- = 12 -RRB- in which rats were only treated with laminectomy without SCI for comparison ; -LRB- 2 -RRB- sham group -LRB- = 12 -RRB- in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	12946
control	12950
group -LRB- = 12 -RRB-	12958
group	12958
= 12	12968
in which rats were only treated with laminectomy without SCI for comparison ; -LRB- 2 -RRB- sham group -LRB- = 12 -RRB- in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	12974
rats	12983
laminectomy	13011
SCI for comparison	13031
SCI	13031
comparison	13039
-LRB- 2 -RRB- sham group -LRB- = 12 -RRB- in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	13051
sham	13055
group -LRB- = 12 -RRB-	13060
group	13060
= 12	13070
in which DMEM culture medium was administered by intraspinal injection ; -LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	13076
DMEM culture medium	13085
intraspinal injection	13125
-LRB- 3 -RRB- OECs treated group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	13148
OECs	13152
group -LRB- = 12 -RRB- which received 3 × 105 OECs by intraspinal injection	13165
group	13165
= 12	13175
3 × 105 OECs by intraspinal injection	13196
3 × 105 OECs	13196
intraspinal injection	13212
-LRB- 4 -RRB- BMSCs treated group -LRB- = 12 -RRB- which received 3 × 105 BMSCs by intraspinal injection	13235
BMSCs	13239
group -LRB- = 12 -RRB- which received 3 × 105 BMSCs by intraspinal injection	13253
group	13253
= 12	13263
3 × 105 BMSCs by intraspinal injection	13284
3 × 105 BMSCs	13284
intraspinal injection	13301
105 OECs and BMSCs in the same way	13324
105 OECs and BMSCs	13324
the same way	13346
BMSCs	13360
a concentration of 1 × 106 cells/100 , which were used for transplantation	13386
a concentration	13386
1 × 106 cells/100 , which were used for transplantation	13405
1 × 106 cells/100	13405
transplantation	13448
Rats	13465
7 days	13487
SCI	13506
the rats	13515
transplantation	13546
aHamilton syringe -LRB- Sigma , USA -RRB- which was attached to a microinjector through a customized needle with a sterile 30-gauge needle	13582
aHamilton syringe	13582
Sigma	13601
USA	13608
a microinjector	13635
a customized needle with a sterile 30-gauge needle	13659
a customized needle	13659
a sterile 30-gauge needle	13684
A small hole	13711
the dura at the injection site.Then	13736
the dura	13736
the injection site.Then	13748
the customized needle	13773
the spinal cord at the midline	13813
the spinal cord	13813
the midline	13832
a depth of 1 to 1.5 mm	13847
a depth	13847
1 to 1.5 mm	13858
30 cell suspension at 1 × 106 cells/100 of the cell suspension	13871
30 cell suspension	13871
1 × 106 cells/100 of the cell suspension	13897
1 × 106 cells/100	13897
the cell suspension	13922
2 minutes	13965
The needle	13976
place for 2 minutes	13999
place	13999
2 minutes	14009
injection	14025
withdrawal	14042
cell leakage	14065
The OECs and the combination of OECs and BMSCs	14079
The OECs	14079
the combination of OECs and BMSCs	14092
the combination	14092
OECs and BMSCs	14111
the spinal cord in the same manner	14149
the spinal cord	14149
the same manner	14168
the combination of OECs and BMSCs	14189
the combination	14189
OECs and BMSCs	14208
the spinal cord with 15 BMSCs cell suspension	14245
the spinal cord	14245
15 BMSCs cell suspension	14266
1 × 106 cells/100 suspensionat 1 × 106 cells/100	14297
1 ×	14297
106 cells/100 suspensionat 1 × 106 cells/100	14301
106 cells/100 suspensionat	14301
1 × 106 cells/100	14345
The sham group	14368
DMEM culture medium and serum `` transplanted '' in the same way	14387
DMEM culture medium	14387
serum `` transplanted '' in the same way	14411
serum	14411
the same way	14435
2.5	14449
Histopathological Examination .	14454
14 and 28 days posttransplantation , ratswere deeply anesthetized	14485
14 and 28 days posttransplantation , ratswere	14485
14 and 28 days	14485
posttransplantation	14500
ketamine	14555
xylazine	14565
The spinal cord tissues	14575
a razor blade	14630
10 % -LRB- v/v -RRB-	14662
10 %	14662
v/v	14666
neutral phosphate-buffered formalin solution	14671
The tissues	14717
paraffin blocks	14746
5 slice	14778
the glass slides	14807
hematoxylin and eosin -LRB- H&E -RRB- for histopathological evaluation	14842
hematoxylin and eosin -LRB- H&E -RRB-	14842
hematoxylin and eosin	14842
H&E	14865
histopathological evaluation	14874
the lightmicroscope -LRB- LeicaDM4000M , Germany -RRB-	14909
the lightmicroscope	14909
LeicaDM4000M	14930
Germany	14943
the photos	14956
optical microscope -LRB- Leica DM4000M , Germany -RRB-	14984
optical microscope	14984
Leica DM4000M	15004
Germany	15019
The identity and analysis of the pathology sections	15028
The identity and analysis	15028
the pathology sections	15057
the pathologists	15094
the results	15116
other certified veterinary pathologists	15149
2.6	15190
Detection of Apoptosis .	15195
Detection	15195
Apoptosis	15208
14 and 28 days after transplantation , rats	15219
14 and 28 days	15219
transplantation , rats	15240
transplantation	15240
rats	15257
ketamine/xylazine	15292
The spinal cord tissues of the rats	15311
The spinal cord tissues	15311
the rats	15338
a terminal deoxynucleotide transferase dUTP nick end labeling -LRB- TUNEL -RRB-	15375
a terminal deoxynucleotide transferase dUTP nick end labeling	15375
TUNEL	15438
cell death detection kit	15459
the manufacturer 's instructions -LRB- Chemicon International Inc. , Temecula , CA -RRB-	15497
the manufacturer 's instructions	15497
the manufacturer 's	15497
Chemicon International Inc.	15530
Temecula	15559
CA	15569
rats -LRB- = 4 -RRB- from normal control , treated , and sham control groups	15583
rats -LRB- = 4 -RRB-	15583
rats	15583
= 4	15592
normal control , treated , and sham control groups	15602
normal control , treated ,	15602
normal control	15602
sham control groups	15631
4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	15676
4 % paraformaldehyde	15676
0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	15699
0.1 M phosphate buffer	15699
pH 7.4	15722
the sections	15736
proteinase K -LRB- 100 / mL -RRB- , rinsed , incubated in 3 % H2O2 , andwashedwith PBS for 10 min followed by washing with permeabilization solution -LRB- 0.1 % Triton X-100 , 0.1 % sodium citrate -RRB- for 5 min	15769
proteinase K -LRB- 100 / mL -RRB- , rinsed , incubated in 3 % H2O2 , andwashedwith PBS for 10 min followed by washing with permeabilization solution -LRB- 0.1 % Triton X-100 , 0.1 % sodium citrate -RRB-	15769
proteinase K -LRB- 100 / mL -RRB- , rinsed , incubated in 3 % H2O2 , andwashedwith PBS for 10 min followed by washing with permeabilization solution	15769
proteinase K -LRB- 100 / mL -RRB-	15769
proteinase K	15769
100	15783
mL	15791
3 % H2O2	15817
andwashedwith PBS for 10 min followed by washing with permeabilization solution	15825
andwashedwith PBS	15825
10 min	15847
permeabilization solution	15878
0.1 % Triton X-100 , 0.1 % sodium citrate	15905
0.1 % Triton X-100	15905
0.1 % sodium citrate	15924
5 min	15949
the sections	15961
PBS	15997
TUNEL reactionmixture	16015
they	16056
converter-PODwith 0.02 % 3,3 - diaminobenzidine -LRB- DAB -RRB-	16083
0.02 % 3,3 - diaminobenzidine -LRB- DAB -RRB-	16101
0.02 % 3,3	16101
0.02 %	16101
3,3	16106
diaminobenzidine -LRB- DAB -RRB-	16112
diaminobenzidine	16112
DAB	16130
Mayer 's hematoxylin	16136
Mayer 's	16136
counter-staining	16169
The sections	16187
gelatin-coated slides	16226
they	16257
air-dried overnight at room temperature	16267
air-dried overnight	16267
room temperature	16290
Yellow stained nucleus	16308
Yellow	16308
nucleus	16323
TUNEL-positive cells	16335
TUNEL-positive cell quantitative method	16357
TUNEL-positive cell	16357
quantitative method	16377
each group	16410
5 cases of well-stained sections	16422
5 cases	16422
well-stained sections	16433
10 times for observation	16483
10 times	16483
observation	16496
the microscope objective	16514
5 high power fields -LRB- × 400 -RRB- in each sectionwere randomly selected , and a total of 25 high power fields	16540
5 high power fields -LRB- × 400 -RRB-	16540
5 high power fields	16540
× 400	16561
each sectionwere randomly selected , and a total of 25 high power fields	16570
each sectionwere randomly selected	16570
each sectionwere	16570
a total of 25 high power fields	16610
a total	16610
25 high power fields	16621
computer -LRB- resolution is 800 × 600 -RRB-	16665
computer	16665
resolution	16675
800 × 600	16689
800 ×	16689
600	16695
Q550CW image signal acquisition and analysis system	16701
Q550CW image signal acquisition	16701
analysis system	16737
intestinal epithelial cell apoptosis index	16779
The number of apoptotic cells/the total cell number × 100 %	16823
The number	16823
apoptotic cells/the total cell number × 100 %	16837
apoptotic cells/the total cell number	16837
the apoptosis rate of this field	16888
the apoptosis rate	16888
this field	16910
the average rate of apoptosis of five fields	16926
the average rate	16926
apoptosis of five fields	16946
apoptosis	16946
five fields	16959
the apoptosis rate of rat spinal cord cells in the group	16975
the apoptosis rate	16975
rat spinal cord cells	16997
the group	17022
2.7	17033
Western Blot Assay .	17038
Western Blot	17038
Assay	17051
Western blot	17058
protein expression of Bax , Bcl-2 , Caspase-9 , and Caspase-3	17090
protein expression	17090
Bax , Bcl-2 , Caspase-9 , and Caspase-3	17112
Bax	17112
Bcl-2 , Caspase-9 , and Caspase-3	17117
transplantation -LRB- OECs , BMSCs , and OECs and BMSCs , resp . -RRB-	17175
transplantation	17175
OECs , BMSCs , and OECs and BMSCs , resp	17192
OECs	17192
BMSCs	17198
OECs and BMSCs , resp	17209
OECs and BMSCs	17209
resp	17225
14 days and 28 days	17236
14 days	17236
28 days	17248
rats	17257
5 mm lengths of spinal cord centered on T10	17283
5 mm lengths	17283
spinal cord centered on T10	17298
spinal cord	17298
T10	17322
−	17371
70 ∘ C	17372
necessary for further experimentation.The tissues	17383
further experimentation.The	17397
0.2 mL of homogenization buffer followed by centrifuge for 10 min -LRB- 12,000 r/min , at 4 ∘ C -RRB-	17469
0.2 mL	17469
homogenization buffer followed by centrifuge for 10 min -LRB- 12,000 r/min , at 4 ∘ C -RRB-	17478
homogenization buffer	17478
centrifuge for 10 min -LRB- 12,000 r/min , at 4 ∘ C -RRB-	17512
centrifuge	17512
10 min -LRB- 12,000 r/min , at 4 ∘ C -RRB-	17527
10 min	17527
12,000 r/min , at 4 ∘ C	17535
12,000 r/min	17535
4 ∘ C	17552
The supernatants	17558
protein determination	17594
Protein samples -LRB- 50 -RRB-	17617
Protein samples	17617
50	17634
SDSPAGE	17660
12 %	17669
gels , 5 % stacking gels	17683
gels	17683
gels	17701
PVDF membranes -LRB- 150 mA , 1.5 h -RRB- -LRB- Millipore Corporation , USA -RRB-	17726
PVDF membranes -LRB- 150 mA , 1.5 h -RRB-	17726
PVDF membranes	17726
150 mA , 1.5 h	17742
150 mA	17742
1.5 h	17750
Millipore Corporation	17758
USA	17781
5 % nonfat dry milk	17807
the membraneswere incubatedwith	17827
different primary antibodies including anti-Bax , anti-Bcl-2 -LRB- Abcam , USA -RRB-	17859
different primary antibodies	17859
anti-Bax , anti-Bcl-2 -LRB- Abcam , USA -RRB-	17898
anti-Bax	17898
anti-Bcl-2 -LRB- Abcam , USA -RRB-	17908
anti-Bcl-2	17908
Abcam	17920
USA	17927
anti-Caspase - 9 , anti-Caspase-3 , and anti-GAPDH -LRB- Sigma , USA -RRB- overnight at 4 ∘ C	17933
9 , anti-Caspase-3 , and anti-GAPDH -LRB- Sigma , USA -RRB- overnight at 4 ∘	17947
9 , anti-Caspase-3 , and anti-GAPDH -LRB- Sigma , USA -RRB- overnight	17947
9 , anti-Caspase-3 , and anti-GAPDH -LRB- Sigma , USA -RRB-	17947
9	17947
anti-Caspase-3	17950
anti-GAPDH -LRB- Sigma , USA -RRB-	17970
anti-GAPDH	17970
Sigma	17982
USA	17989
4 ∘	18007
washingmembranes with TBST	18018
washingmembranes	18018
TBST	18040
the membranes	18046
goat anti-mouse IgG-HRP conjugated secondary antibody -LRB- Sigma , USA -RRB- at a 1 : 1000 dilution for 1.5 h at roomtemperature	18080
goat anti-mouse IgG-HRP	18080
secondary antibody -LRB- Sigma , USA -RRB- at a 1 : 1000 dilution for 1.5 h	18115
secondary antibody -LRB- Sigma , USA -RRB- at a 1	18115
secondary antibody -LRB- Sigma , USA -RRB-	18115
secondary antibody	18115
Sigma	18135
USA	18142
a 1	18150
1000 dilution for 1.5 h	18156
1000 dilution	18156
1.5 h	18174
roomtemperature	18183
the proteinswere	18209
an enhanced chemiluminescence detection system	18243
ECL detection kit , Pierce	18291
ECL detection kit	18291
Pierce	18310
The membranes	18319
AR film -LRB- Eastman Kodak Company , USA -RRB-	18355
AR film	18355
Eastman Kodak Company	18364
USA	18387
the results	18396
densitometric analysis -LRB- MAISIQI HIGH-TECH Co. , Ltd , MSD-26 , China -RRB-	18432
densitometric analysis	18432
MAISIQI HIGH-TECH Co. , Ltd , MSD-26 , China	18456
MAISIQI HIGH-TECH Co.	18456
Ltd	18479
MSD-26	18484
China	18492
Experiments	18500
triplicate	18530
reproducibility	18551
2.8	18568
Behavioral Assessment after SCI .	18573
Behavioral Assessment	18573
SCI	18601
The recovery of gross motor function	18606
The recovery	18606
gross motor function	18622
Basso , Beattie , and Bresnahan -LRB- BBB -RRB- locomotor rating scale	18663
Basso	18663
Beattie	18670
Bresnahan -LRB- BBB -RRB- locomotor rating scale	18683
Bresnahan	18683
BBB	18694
locomotor rating scale	18699
the procedure described in Basso et al. -LSB- 26 -RSB-	18732
the procedure	18732
Basso et al. -LSB- 26 -RSB-	18759
Basso et al. -LSB-	18759
The scale used for measuring hind limb function with these procedures	18778
The scale	18778
hind limb function	18807
these procedures	18831
complete paralysis -LRB- score 0 -RRB- to normal gait -LRB- score 21 -RRB- , with an increasing score indicating the degree in use of individual joints , weight-bearing , coordinated limb movement , coordinated joint movement , and other functions	18860
complete paralysis -LRB- score 0 -RRB- to normal gait -LRB- score 21 -RRB-	18860
complete paralysis -LRB- score 0 -RRB-	18860
complete paralysis	18860
score 0	18880
normal gait -LRB- score 21 -RRB-	18892
normal gait	18892
score 21	18905
an increasing score indicating the degree in use of individual joints , weight-bearing , coordinated limb movement , coordinated joint movement , and other functions	18921
an increasing score	18921
the degree in use of individual joints , weight-bearing , coordinated limb movement , coordinated joint movement , and other functions	18952
the degree in use of individual joints , weight-bearing , coordinated limb movement , coordinated joint movement	18952
the degree in use of individual joints	18952
the degree	18952
use of individual joints	18966
use	18966
individual joints	18973
weight-bearing	18992
limb movement	19020
joint movement	19047
other functions	19067
Locomotion	19084
digital video camera at each time point	19111
digital video camera	19111
each time point	19135
two blind researchers	19167
Rats	19190
the open field for the test	19224
the open field	19224
the test	19243
a rat	19259
the open field , two investigators conducted	19292
the open field	19292
two investigators conducted	19308
two investigators	19308
4-minute testing sessions on each leg	19336
4-minute testing sessions	19336
each leg	19365
Two individuals `` blinded '' to rat treatment status	19375
Two individuals	19375
rat treatment status	19404
the open field test at least once a week	19435
the open field test	19435
once a week	19464
day 1	19481
SCI	19493
4 weeks -LRB- 1 , 7 , 8 , 10 , 14 , 21 , 28 , and 35 days after SCI -RRB- after laminectomy for all animals in the study	19500
4 weeks -LRB- 1 , 7 , 8 , 10 , 14 , 21 , 28 , and 35 days after SCI -RRB-	19500
1 , 7 , 8 , 10 , 14 , 21 , 28 , and 35 days after SCI	19509
1	19509
7	19512
8	19515
10	19518
14	19522
21	19526
28	19530
35 days after SCI	19538
35 days	19538
SCI	19552
laminectomy for all animals in the study	19563
laminectomy	19563
all animals in the study	19579
all animals	19579
the study	19594
Behavioral outcomes and examples of specific BBB locomotor scores	19605
Behavioral outcomes and examples	19605
specific BBB locomotor scores	19641
digital video	19691
2.9	19706
Statistical Analysis .	19711
Quantitative data from open field locomotor scores , detection of apoptosis , and Western blot analysis	19733
Quantitative data	19733
open field locomotor scores , detection of apoptosis , and Western blot analysis	19756
open field locomotor scores	19756
detection of apoptosis	19785
detection	19785
apoptosis	19798
Western blot analysis	19813
statistical significance	19854
one-way Analysis of Variance -LRB- ANOVA -RRB-	19882
one-way Analysis	19882
Variance -LRB- ANOVA -RRB-	19902
Variance	19902
ANOVA	19912
replications	19924
Data for each group	19938
Data	19938
each group	19947
mean ± SD	19978
other groups for significance	20006
other groups	20006
significance	20023
ANOVA followed by least significant difference -LRB- LSD -RRB- test to compare the differences between groups	20039
ANOVA	20039
least significant difference -LRB- LSD -RRB- test	20057
LSD	20087
the differences between groups	20108
the differences	20108
groups	20132
Results	20140
Results Table 1 : The change of body weight for rats after surgery -LRB- g , ± SD -RRB- .	20208
Results Table 1	20208
Results	20208
Table 1	20216
The change of body weight for rats after surgery -LRB- g , ± SD -RRB-	20224
The change	20224
body weight for rats after surgery -LRB- g , ± SD -RRB-	20238
body weight	20238
rats after surgery -LRB- g , ± SD -RRB-	20254
rats	20254
surgery -LRB- g , ± SD -RRB-	20265
surgery	20265
g , ± SD	20274
g	20274
± SD	20280
Table 2 : BBB scores of rats with SCI before transplantation at 1 day and 7 days after SCI -LRB- ± SD -RRB- .	20288
Table 2	20288
BBB scores of rats with SCI before transplantation at 1 day and 7 days after SCI -LRB- ± SD -RRB-	20297
BBB scores	20297
rats with SCI before transplantation at 1 day and 7 days after SCI -LRB- ± SD -RRB-	20311
rats	20311
SCI before transplantation at 1 day and 7 days after SCI -LRB- ± SD -RRB-	20321
SCI	20321
transplantation at 1 day and 7 days after SCI -LRB- ± SD -RRB-	20332
transplantation at 1 day	20332
transplantation	20332
1 day	20351
7 days after SCI -LRB- ± SD -RRB-	20361
7 days	20361
SCI -LRB- ± SD -RRB-	20374
SCI	20374
± SD	20382
Table 3 : BBB scores of rats with SCI after OECs and MSCs transplantation treatments -LRB- ± SD -RRB- .	20390
Table 3	20390
BBB scores of rats with SCI after OECs and MSCs transplantation treatments -LRB- ± SD -RRB-	20399
BBB scores	20399
rats with SCI after OECs and MSCs transplantation treatments -LRB- ± SD -RRB-	20413
rats	20413
SCI after OECs and MSCs transplantation treatments -LRB- ± SD -RRB-	20423
SCI	20423
OECs and MSCs transplantation treatments -LRB- ± SD -RRB-	20433
OECs and MSCs transplantation treatments	20433
± SD	20478
Figure 3 : The growth curve of OECs , BMSCs , and coculture cells .	20486
Figure 3	20486
The growth curve of OECs , BMSCs , and coculture cells	20496
The growth curve	20496
OECs , BMSCs , and coculture cells	20516
Figure 1 : Animal experimental design of antiapoptotic effects of cotransplantation of OECs and BMSCs in adult rats .	20551
Figure 1	20551
Animal experimental design of antiapoptotic effects of cotransplantation of OECs and BMSCs in adult rats	20561
Animal experimental design	20561
antiapoptotic effects of cotransplantation of OECs and BMSCs in adult rats	20591
antiapoptotic effects	20591
cotransplantation of OECs and BMSCs in adult rats	20616
cotransplantation	20616
OECs and BMSCs in adult rats	20637
OECs and BMSCs	20637
adult rats	20655
Figure 2 : Morphological features ofOECs , BMSCs , and coculture cells -LRB- × 200 -RRB- .	20668
Figure 2	20668
Morphological features ofOECs , BMSCs , and coculture cells -LRB- × 200 -RRB-	20677
Morphological features ofOECs	20677
BMSCs	20708
coculture cells -LRB- × 200 -RRB-	20719
coculture cells	20719
× 200	20736
OECs	20742
bipolar andmultipolar , woven into a net -LRB- a -RRB-	20752
bipolar andmultipolar	20752
a net -LRB- a -RRB-	20786
a net	20786
OECs	20796
p75NTR -LRB- green , b -RRB-	20822
p75NTR	20822
green , b	20830
green	20830
b	20837
BMSCs	20841
the shape	20864
spindle -LRB- c -RRB-	20883
spindle	20883
c	20892
Brdu	20896
the cell core -LRB- red , d -RRB-	20923
the cell core	20923
red , d	20938
red	20938
d	20943
The coculture cells , OECs	20947
the cell membrane -LRB- green , e -RRB- and cell core -LRB- yellow , e -RRB- -LRB- red arrow -RRB- ; BMSCs were identified in the cell core -LRB- red , f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green , f -RRB-	20992
the cell membrane	20992
green , e -RRB- and cell core -LRB- yellow , e -RRB- -LRB- red arrow -RRB- ; BMSCs were identified in the cell core -LRB- red , f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green , f	21011
green	21011
e -RRB- and cell core -LRB- yellow , e -RRB- -LRB- red arrow -RRB- ; BMSCs were identified in the cell core -LRB- red , f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green , f	21018
and cell	21021
core -LRB- yellow , e -RRB-	21030
core	21030
yellow	21036
e	21044
-LRB- red arrow -RRB- ; BMSCs were identified in the cell core -LRB- red , f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green , f	21047
-LRB- red arrow -RRB-	21047
BMSCs	21060
the cell core -LRB- red , f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green , f	21085
the cell core	21085
red , f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green ,	21100
red	21100
f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green ,	21105
-LRB- white arrow -RRB-	21108
not in the cell membrane -LRB- green ,	21126
not in the cell membrane	21126
not	21126
the cell membrane	21133
green	21152
Figure 5 : Cellular apoptosis after spinal cord injury was reduced by OECs and BMSCs -LRB- TUNEL staining , 10 × 40 -RRB- .	21164
Figure 5	21164
Cellular apoptosis after spinal cord injury was reduced by OECs and BMSCs -LRB- TUNEL staining , 10 × 40 -RRB-	21174
Cellular apoptosis	21174
spinal cord injury	21199
OECs and BMSCs -LRB- TUNEL staining , 10 × 40 -RRB-	21233
OECs and BMSCs	21233
TUNEL staining , 10 × 40	21249
TUNEL staining	21249
10 × 40	21265
10	21265
40	21270
-LRB- A -RRB- 14 days after transplantation ; -LRB- B -RRB- 28 days after transplantation ; -LRB- a1 , a2 -RRB- control group ; -LRB- b1 , b2 -RRB- sham group ; -LRB- c1 , c2 -RRB- OECs treated group ; -LRB- d1 , d2 -RRB- BMSCs treated group ; -LRB- e1 , e2 -RRB- cotransplant treated group	21281
-LRB- A -RRB-	21281
14 days	21285
transplantation ; -LRB- B -RRB- 28 days after transplantation ; -LRB- a1 , a2 -RRB- control group ;	21299
transplantation	21299
-LRB- B -RRB- 28 days after transplantation ; -LRB- a1 , a2 -RRB- control group	21316
-LRB- B -RRB-	21316
28 days after transplantation ; -LRB- a1 , a2 -RRB- control group	21320
28 days	21320
transplantation	21334
a1 , a2	21352
a1	21352
a2	21356
b1 , b2	21376
b1	21376
b2	21380
sham group ; -LRB- c1 , c2 -RRB- OECs treated group ; -LRB- d1 , d2 -RRB- BMSCs treated group ; -LRB- e1 , e2 -RRB- cotransplant treated group	21384
sham group	21384
-LRB- c1 , c2 -RRB- OECs treated group ; -LRB- d1 , d2 -RRB- BMSCs treated group ; -LRB- e1 , e2 -RRB- cotransplant treated group	21396
-LRB- c1 , c2 -RRB- OECs	21396
c1 , c2	21397
c1	21397
c2	21401
group ; -LRB- d1 , d2 -RRB- BMSCs treated group ; -LRB- e1 , e2 -RRB-	21418
group ; -LRB- d1 , d2 -RRB- BMSCs treated group ;	21418
group	21418
-LRB- d1 , d2 -RRB- BMSCs treated group	21425
-LRB- d1 , d2 -RRB- BMSCs	21425
d1 , d2	21426
d1	21426
d2	21430
group	21448
e1 , e2	21456
e1	21456
e2	21460
cotransplant treated group	21464
-LRB- C -RRB- The spinal cord cell apoptosis rate of rats in each group .	21492
The spinal cord cell apoptosis rate	21495
rats in each group	21534
rats	21534
each group	21542
a < 0.05 versus control group ; b < 0.05 versus sham group ; c < 0.05 versus OECs treated group ; and d < 0.05 versus BMSCs treated group .	21554
a < 0.05 versus control group	21554
a < 0.05	21554
control group	21573
b < 0.05 versus sham group ; c < 0.05 versus OECs treated group ; and d < 0.05 versus BMSCs treated group	21588
b < 0.05 versus sham group ; c < 0.05	21588
b < 0.05 versus sham group ; c <	21588
0.05	21594
sham group ; c	21606
sham group	21606
c	21618
0.05	21625
OECs treated group ; and d < 0.05 versus BMSCs treated group	21637
OECs treated group ; and d < 0.05	21637
OECs	21637
group	21650
<	21666
BMSCs treated group	21680
BMSCs	21680
group	21694
Figure 6 : The expression on Bax , Bcl-2 , Caspase-9 , Caspase-3 , and GADPH protein in spinal cord 14 days and 28 days after transplantation .	21702
Figure 6	21702
The expression on Bax , Bcl-2 , Caspase-9 , Caspase-3 , and GADPH protein in spinal cord 14 days and 28 days after transplantation	21711
The expression	21711
Bax , Bcl-2 , Caspase-9 , Caspase-3 , and GADPH protein	21729
spinal cord 14 days and 28 days after transplantation	21784
spinal cord 14 days	21784
spinal cord	21784
14 days	21796
28 days after transplantation	21808
28 days	21808
transplantation	21822
-LRB- a -RRB- Western blot analysis of Bax , Bcl-2 , Caspase-9 , Caspase-3 , andGADPHproteins of spinal cord .	21839
Western blot analysis	21842
Bax , Bcl-2 , Caspase-9 , Caspase-3 , andGADPHproteins of spinal cord	21867
Bax	21867
Bcl-2	21872
Caspase-9	21878
Caspase-3	21888
andGADPHproteins of spinal cord	21899
andGADPHproteins	21899
spinal cord	21919
-LRB- b -RRB- Relative ratio of Bax protein .	21932
Relative ratio	21936
Bax protein	21954
-LRB- c -RRB- Relative ratio of Bcl-2 protein .	21967
Relative ratio	21971
Bcl-2 protein	21989
-LRB- d -RRB- Relative ratio of Caspase-9 protein .	22004
Relative ratio	22008
Caspase-9 protein	22026
-LRB- e -RRB- Relative ratio of Caspase-3 protein .	22045
Relative ratio	22049
Caspase-3 protein	22067
a < 0.05 versus control group ; b < 0.05 versus sham group ; c < 0.05 versus OECs treated group ; and d < 0.05 versus BMSCs treated group .	22086
a < 0.05 versus control group	22086
a < 0.05	22086
control group	22105
b < 0.05 versus sham group ; c < 0.05 versus OECs treated group ; and d < 0.05 versus BMSCs treated group	22120
b < 0.05 versus sham group ; c < 0.05	22120
b < 0.05 versus sham group ; c <	22120
0.05	22127
sham group ; c	22139
sham group	22139
c	22151
0.05	22158
OECs treated group ; and d < 0.05 versus BMSCs treated group	22170
OECs treated group ; and d < 0.05	22170
OECs	22170
group	22183
<	22199
BMSCs treated group	22213
BMSCs	22213
group	22227
3.1	22235
Culture and Identification of Stem Cells .	22240
Culture and Identification	22240
Stem Cells	22270
microcode	22288
theOECswerebipolar ormultipolar andcellprotrusion	22299
a net on the fifth day	22386
a net	22386
the fifth day	22395
The OECs	22410
positive staining -LRB- green , under fluorescent microscope -RRB- with p75 antibody -LRB- Figures 2 -LRB- a -RRB- and 2 -LRB- b -RRB- -RRB-	22438
positive staining -LRB- green , under fluorescent microscope -RRB-	22438
positive staining	22438
green , under fluorescent microscope	22457
green	22457
fluorescent microscope	22470
p75 antibody -LRB- Figures 2 -LRB- a -RRB- and 2 -LRB- b -RRB- -RRB-	22499
p75 antibody	22499
Figures 2 -LRB- a -RRB- and 2 -LRB- b -RRB-	22513
Figures	22513
2 -LRB- a -RRB- and 2 -LRB- b -RRB-	22521
2 -LRB- a -RRB-	22521
2	22521
a	22523
2 -LRB- b -RRB-	22530
2	22530
b	22532
The BMSCs	22537
the shape of spindle	22554
the shape	22554
spindle	22567
the fifth day	22634
Immunofluorescence staining with Brdu	22649
Immunofluorescence staining	22649
Brdu	22682
the color of nucleus	22699
the color	22699
nucleus	22712
Figures 2 -LRB- c -RRB- and 2 -LRB- d -RRB-	22729
Figures	22729
2 -LRB- c -RRB- and 2 -LRB- d -RRB-	22737
2 -LRB- c -RRB-	22737
2 -LRB- d -RRB-	22746
OECs or BMSCs	22767
the coculture cells	22782
complete adherent 24 h	22807
24	22825
protrusion	22841
fifth day	22866
coculture cells	22876
bipolar triode or multipolar one	22923
bipolar triode	22923
multipolar one	22941
the OECs or BMSCs	22961
protrusion	22994
The cells with green cell membrane and yellow cell nuclear	23018
The cells	23018
green cell membrane and yellow cell nuclear	23033
green cell membrane	23033
yellow cell nuclear	23057
OECs	23082
cells with red nuclear	23092
cells	23092
red nuclear	23103
BMSCs	23120
green cell membrane	23134
There	23155
much difference	23169
rate of these two kinds of cells -LRB- Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB- -RRB-	23188
rate	23188
these two kinds of cells -LRB- Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB- -RRB-	23196
these two kinds	23196
cells -LRB- Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB- -RRB-	23215
cells	23215
Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB-	23222
Figures	23222
2 -LRB- e -RRB- and 2 -LRB- f -RRB-	23230
2 -LRB- e -RRB-	23230
2	23230
e	23232
2 -LRB- f -RRB-	23239
2	23239
f	23241
The membrane and cell protrusion of OECs	23246
The membrane and cell protrusion	23246
OECs	23282
fluorescence	23304
the cells shape	23318
bipolar triode and multipolar model -LRB- Figures 2 -LRB- a -RRB- and 2 -LRB- b -RRB- -RRB-	23341
bipolar triode and multipolar model	23341
Figures 2 -LRB- a -RRB- and 2 -LRB- b -RRB-	23378
Figures	23378
2 -LRB- a -RRB- and 2 -LRB- b -RRB-	23386
2 -LRB- a -RRB-	23386
2	23386
a	23388
2 -LRB- b -RRB-	23395
2	23395
b	23397
the BMSCs shape	23406
spindle	23426
the fifth day	23493
the shape	23508
the spindle	23533
the growth direction	23550
Immunofluorescence staining	23584
the color of nucleus	23619
the color	23619
nucleus	23632
Figures 2 -LRB- c -RRB- and 2 -LRB- d -RRB-	23649
Figures	23649
2 -LRB- c -RRB- and 2 -LRB- d -RRB-	23657
2 -LRB- c -RRB-	23657
2 -LRB- d -RRB-	23666
We	23673
the morphology observation and identification of coculture cells	23680
the morphology observation and identification	23680
coculture cells	23729
Cells	23746
complete adherent 24 h	23757
24	23775
protrusion	23791
fifth day	23816
cells	23826
bipolar triode or multipolar model	23863
bipolar triode	23863
multipolar model	23881
other cells	23899
protrusion	23927
The positive cells with green cell membrane and yellow cell nuclear	23951
The positive cells	23951
green cell membrane and yellow cell nuclear	23975
green cell membrane	23975
yellow cell nuclear	23999
OECs	24024
cells with red nuclear	24030
cells	24030
red nuclear	24041
BMSCs	24058
green cell membrane.The rate of two kinds of cells was not different significantly -LRB- Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB- -RRB-	24072
green cell membrane.The rate	24072
two kinds of cells was not different significantly -LRB- Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB- -RRB-	24104
two kinds	24104
cells was not different significantly	24117
cells	24117
Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB-	24156
Figures	24156
2 -LRB- e -RRB- and 2 -LRB- f -RRB-	24164
2 -LRB- e -RRB-	24164
2	24164
e	24166
2 -LRB- f -RRB-	24173
2	24173
f	24175
3.2	24180
The Viability of OECs , BMSCs , and Coculture Cells .	24185
The Viability	24185
OECs , BMSCs , and Coculture Cells	24202
All cells	24236
similar growth rate	24253
Lowproliferation of the cells	24274
Lowproliferation	24274
the cells	24294
the first two days	24317
it	24340
day 2	24359
day 6 after which it maintained the similar level as shown in Figure 1	24368
day 6	24368
it	24386
the similar level	24400
Figure 1	24430
the growth curve of OECs and BMSCs	24458
the growth curve	24458
OECs and BMSCs	24478
the coculture cells curve	24494
Figure 3	24549
3.3	24560
The Change of Body Weight for Rats after Surgery .	24565
The Change	24565
Body Weight for Rats	24579
Body Weight	24579
Rats	24595
Surgery	24606
All the rats	24615
2 -- 4 hours after surgery	24643
2	24643
4 hours after surgery	24645
4 hours	24645
surgery	24659
6 hours	24698
surgery	24712
The rats ' diet	24721
The rats '	24721
normal after three day postsurgery	24748
three day	24761
The body weight of rats in the control group	24784
The body weight	24784
rats in the control group	24803
rats	24803
the control group	24811
the observation period	24860
the body weight of rats in the sham group , OECs treated group , BMSCs treated group , and cotransplant treated group	24888
the body weight of rats in the sham group , OECs treated group	24888
the body weight	24888
rats in the sham group , OECs treated group	24907
rats	24907
the sham group , OECs treated group	24915
the sham group	24915
OECs treated group	24931
OECs	24931
group	24944
BMSCs treated group	24951
BMSCs	24951
group	24965
cotransplant treated group	24976
14 days	25019
surgery -LRB- Table 1 -RRB-	25033
surgery	25033
Table 1	25042
Thebody weight of rats in theOECs treated group , BMSCs treated group , and cotransplant treated group	25051
Thebody weight of rats in theOECs treated group	25051
Thebody weight	25051
rats in theOECs treated group	25069
rats	25069
theOECs treated group	25077
theOECs	25077
group	25093
BMSCs treated group	25100
BMSCs	25100
group	25114
cotransplant treated group	25125
A significant increase in body weight of rats	25173
A significant increase	25173
body weight of rats	25199
body weight	25199
rats	25214
OECs treated group , BMSCs treated group , and cotransplant treated group compared with that in sham group 14 days and 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Table 1 -RRB-	25232
OECs treated group , BMSCs treated group , and cotransplant treated group compared with that in sham group 14 days	25232
OECs treated group	25232
OECs	25232
group	25245
BMSCs treated group	25252
BMSCs	25252
group	25266
cotransplant treated group compared with that in sham group 14 days	25277
cotransplant treated group	25277
that in sham group 14 days	25318
that	25318
sham group	25326
14 days	25337
28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Table 1 -RRB-	25349
28 days	25349
transplantation -LRB- < 0.05 -RRB- -LRB- Table 1 -RRB-	25363
transplantation -LRB- < 0.05 -RRB-	25363
transplantation	25363
< 0.05	25383
<	25383
0.05	25385
Table 1	25392
The higher body weight of rats	25402
The higher body weight	25402
rats	25428
cotransplant treated group 28 days	25446
cotransplant treated group	25446
28 days	25473
transplantation -LRB- < 0.05 -RRB- -LRB- Table 1 -RRB-	25487
transplantation -LRB- < 0.05 -RRB-	25487
transplantation	25487
< 0.05	25507
<	25507
0.05	25509
Table 1	25516
the body weight of rats	25530
the body weight	25530
rats	25549
the presurgery level	25574
the end of the observation period	25601
the end	25601
the observation period	25612
3.4	25636
Pathology Changes in Spinal Cord Tissue .	25641
Pathology Changes	25641
Spinal Cord Tissue	25662
14 and 28 days after transplantation , no abnormality	25682
14 and 28 days	25682
transplantation , no abnormality	25703
transplantation	25703
no abnormality	25720
the control groups	25748
Black and white matter	25768
Black	25768
white matter	25778
integrity boundaries	25795
Cavity , liquefaction , and inflammatory cell infiltration	25817
Cavity	25817
liquefaction	25825
inflammatory cell infiltration	25843
Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100 ; Figure 4 -LRB- A -RRB- , -LRB- a -RRB- × 400 ; and Figure 4 -LRB- B -RRB- , -LRB- a2 -RRB-	25889
Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100 ; Figure 4 -LRB- A -RRB- , -LRB- a -RRB- × 400 ; and Figure 4 -LRB- B -RRB-	25889
Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100 ; Figure 4 -LRB- A -RRB- , -LRB- a -RRB- × 400 ; and Figure 4	25889
Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100	25889
Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB-	25889
Figure 4 -LRB- A -RRB-	25889
Figure 4	25889
A	25898
a1	25903
× 100	25907
Figure 4 -LRB- A -RRB- , -LRB- a -RRB- × 400	25913
Figure	25913
4 -LRB- A -RRB- , -LRB- a -RRB- × 400	25920
4 -LRB- A -RRB- , -LRB- a -RRB-	25920
4 -LRB- A -RRB- ,	25920
4	25920
A	25922
400	25931
Figure 4	25940
B	25949
-LRB- a2 -RRB-	25953
There	25960
no difference in spinal cord stained pictures between 14-day groups -LRB- Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100 -RRB- and 28-day groups -LRB- Figure 4 -LRB- B -RRB- , -LRB- a2 -RRB- × 100 -RRB-	25970
no difference	25970
spinal cord	25987
pictures between 14-day groups -LRB- Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100 -RRB- and 28-day groups -LRB- Figure 4 -LRB- B -RRB- , -LRB- a2 -RRB- × 100 -RRB-	26007
pictures	26007
14-day groups -LRB- Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100 -RRB- and 28-day groups -LRB- Figure 4 -LRB- B -RRB- , -LRB- a2 -RRB- × 100 -RRB-	26024
14-day groups	26024
Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100	26039
Figure	26039
4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100	26046
4 -LRB- A -RRB- , -LRB- a1 -RRB-	26046
4 -LRB- A -RRB-	26046
4	26046
A	26048
a1	26053
× 100	26057
28-day groups	26067
Figure 4 -LRB- B -RRB- , -LRB- a2 -RRB- × 100	26082
Figure	26082
4 -LRB- B -RRB- , -LRB- a2 -RRB- × 100	26089
4 -LRB- B -RRB- , -LRB- a2 -RRB-	26089
4 -LRB- B -RRB-	26089
4	26089
B	26091
a2	26096
× 100	26100
spinal cord injury	26112
the spinal cord structure in sham groups	26132
the spinal cord structure	26132
sham groups	26161
a lot of cavities , liquefaction , and neurons atrophy	26199
a lot	26199
cavities , liquefaction , and neurons atrophy	26208
cavities	26208
liquefaction	26218
neurons atrophy	26236
nerve fibers	26276
arrangement derangement -LRB- Figure 4 -LRB- A -RRB- , -LRB- b1 -RRB- × 100 ; Figure 4 -LRB- A -RRB- , -LRB- b -RRB- × 400 ; Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100 -RRB-	26293
arrangement derangement	26293
Figure 4 -LRB- A -RRB- , -LRB- b1 -RRB- × 100 ; Figure 4 -LRB- A -RRB- , -LRB- b -RRB- × 400 ; Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100	26318
Figure	26318
4 -LRB- A -RRB- , -LRB- b1 -RRB- × 100 ; Figure 4 -LRB- A -RRB- , -LRB- b -RRB- × 400 ; Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100	26325
4 -LRB- A -RRB- , -LRB- b1 -RRB- × 100	26325
4 -LRB- A -RRB- , -LRB- b1 -RRB-	26325
4 -LRB- A -RRB-	26325
4	26325
A	26327
b1	26332
× 100	26336
Figure 4 -LRB- A -RRB- , -LRB- b -RRB- × 400	26342
Figure 4	26342
A	26351
-LRB- b -RRB- × 400	26355
-LRB- b -RRB-	26355
400	26360
Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100	26365
Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB-	26365
Figure 4 -LRB- B -RRB-	26365
Figure 4	26365
B	26374
b2	26379
× 100	26383
The cavity	26389
the OECs treated group -LRB- Figure 4 -LRB- A -RRB- , -LRB- c1 -RRB- × 100 -RRB- , BMSCs groups -LRB- Figure 4 -LRB- A -RRB- , -LRB- d1 -RRB- × 100 -RRB- , and cotransplant groups -LRB- Figure 4 -LRB- A -RRB- , -LRB- e1 -RRB- × 100 -RRB-	26423
the OECs treated group -LRB- Figure 4 -LRB- A -RRB- , -LRB- c1 -RRB- × 100 -RRB-	26423
the OECs	26423
group -LRB- Figure 4 -LRB- A -RRB- , -LRB- c1 -RRB- × 100 -RRB-	26440
group	26440
Figure 4 -LRB- A -RRB- , -LRB- c1 -RRB- × 100	26447
Figure	26447
4 -LRB- A -RRB- , -LRB- c1 -RRB- × 100	26454
4 -LRB- A -RRB- , -LRB- c1 -RRB-	26454
4 -LRB- A -RRB-	26454
4	26454
A	26456
c1	26461
× 100	26465
BMSCs groups -LRB- Figure 4 -LRB- A -RRB- , -LRB- d1 -RRB- × 100 -RRB-	26472
BMSCs groups	26472
Figure 4 -LRB- A -RRB- , -LRB- d1 -RRB- × 100	26486
Figure 4 -LRB- A -RRB- , -LRB- d1 -RRB-	26486
Figure 4 -LRB- A -RRB-	26486
Figure 4	26486
A	26495
d1	26500
× 100	26504
cotransplant groups -LRB- Figure 4 -LRB- A -RRB- , -LRB- e1 -RRB- × 100 -RRB-	26515
cotransplant groups	26515
Figure 4 -LRB- A -RRB- , -LRB- e1 -RRB- × 100	26536
Figure 4 -LRB- A -RRB- , -LRB- e1 -RRB-	26536
Figure 4 -LRB- A -RRB-	26536
Figure 4	26536
A	26545
e1	26550
× 100	26554
The number of cavities induced by spinal cord injury in these three groups	26561
The number	26561
cavities induced by spinal cord injury in these three groups	26575
cavities	26575
spinal cord injury in these three groups	26595
spinal cord injury	26595
these three groups	26617
that in the sham group 14 days	26650
that	26650
the sham group	26658
14 days	26673
transplantation	26687
The cavity	26704
inducedby spinal cord injurywasnosignificant change -LRB- Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100 -RRB- , but there was a decrease in the number of the cavities and increase in the number of nerve cells	26715
inducedby spinal cord	26715
injurywasnosignificant change -LRB- Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100 -RRB-	26737
injurywasnosignificant change	26737
Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100	26768
Figure	26768
4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100	26775
4 -LRB- B -RRB- , -LRB- b2 -RRB-	26775
4 -LRB- B -RRB-	26775
4	26775
B	26777
b2	26782
× 100	26786
there	26797
a decrease in the number of the cavities	26807
a decrease	26807
the number of the cavities	26821
the number	26821
the cavities	26835
increase	26852
the number of nerve cells	26864
the number	26864
nerve cells	26878
Figure 4 -LRB- B -RRB- , -LRB- c2 -RRB- , -LRB- d2 -RRB- , and -LRB- e2 -RRB- × 100	26891
Figure	26891
4 -LRB- B -RRB- , -LRB- c2 -RRB- , -LRB- d2 -RRB- , and -LRB- e2 -RRB- × 100	26898
4 -LRB- B -RRB- , -LRB- c2 -RRB- , -LRB- d2 -RRB- ,	26898
4 -LRB- B -RRB- , -LRB- c2 -RRB-	26898
4 -LRB- B -RRB-	26898
4	26898
B	26900
c2	26905
-LRB- d2 -RRB-	26910
e2	26921
× 100	26925
the most and best obvious change	26942
the most	26942
best obvious change	26955
the cotransplant treated group -LRB- Figure 4 -LRB- B -RRB- , -LRB- e2 -RRB- × 100 -RRB-	26982
the cotransplant	26982
group -LRB- Figure 4 -LRB- B -RRB- , -LRB- e2 -RRB- × 100 -RRB-	27007
group	27007
Figure 4 -LRB- B -RRB- , -LRB- e2 -RRB- × 100	27014
Figure	27014
4 -LRB- B -RRB- , -LRB- e2 -RRB- × 100	27021
4 -LRB- B -RRB- , -LRB- e2 -RRB-	27021
4 -LRB- B -RRB-	27021
4	27021
B	27023
e2	27028
× 100	27032
3.5	27039
Cellular Apoptosis after Spinal Cord Injury	27044
Cellular Apoptosis	27044
Spinal Cord Injury	27069
Olfactory Ensheathing Cells with Bone Marrow Mesenchymal Stem Cells	27103
Olfactory Ensheathing Cells	27103
Bone Marrow Mesenchymal Stem Cells	27136
We	27172
the TUNEL method	27180
the occurrence of apoptosis	27208
the occurrence	27208
apoptosis	27226
the spinal cord	27239
SCI -LRB- Figure 5 -RRB-	27261
SCI	27261
Figure 5	27266
14 and 28 days after transplantation , TUNEL staining results of each group	27277
14 and 28 days	27277
transplantation , TUNEL staining results of each group	27298
transplantation	27298
TUNEL staining results of each group	27315
TUNEL staining results	27315
each group	27341
TUNEL-positive cells	27365
white matter	27414
rats 14 and 28 days	27430
rats	27430
14 and 28 days	27435
transplantation	27456
comparison of the spinal cord cell apoptosis rate showedmuch difference among control group rats and those in the sham groups and OECs	27477
comparison	27477
the spinal cord cell apoptosis rate showedmuch difference among control group rats and those in the sham groups and OECs	27491
the spinal cord cell apoptosis rate showedmuch difference among control group rats	27491
the spinal cord cell apoptosis rate showedmuch difference	27491
control group rats	27555
those in the sham groups and OECs	27578
those	27578
the sham groups and OECs	27587
BMSCs	27621
cotransplant treated groups	27640
14 and 28 days after transplantation -LRB- Figure 5 -LRB- C -RRB- -RRB-	27668
14 and 28 days	27668
transplantation -LRB- Figure 5 -LRB- C -RRB- -RRB-	27689
transplantation	27689
Figure 5 -LRB- C -RRB-	27706
Figure	27706
5 -LRB- C -RRB-	27713
The higher spinal cord cell apoptosis rate in the sham group and OECs treated , BMSCs treated , and cotransplant treated groups	27720
The higher spinal cord cell apoptosis rate in the sham group and OECs treated	27720
The higher spinal cord cell apoptosis rate in the sham group	27720
The higher spinal cord cell apoptosis rate	27720
the sham group	27766
OECs treated	27785
OECs	27785
BMSCs treated	27799
BMSCs	27799
cotransplant treated groups	27818
the control group 14 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- A -RRB- and 5 -LRB- C -RRB- -RRB-	27873
the control group	27873
14 days	27891
transplantation -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- A -RRB- and 5 -LRB- C -RRB- -RRB-	27905
transplantation -LRB- < 0.05 -RRB-	27905
transplantation	27905
< 0.05	27925
<	27925
0.05	27927
Figures 5 -LRB- A -RRB- and 5 -LRB- C -RRB-	27934
Figures	27934
5 -LRB- A -RRB- and 5 -LRB- C -RRB-	27942
5 -LRB- A -RRB-	27942
5 -LRB- C -RRB-	27951
The spinal cord cell apoptosis rate in the OECs treated , BMSCs treated , and cotransplant treated groups	27958
The spinal cord cell apoptosis rate in the OECs treated	27958
The spinal cord cell apoptosis rate	27958
the OECs treated	27997
the OECs	27997
BMSCs treated	28015
BMSCs	28015
cotransplant treated groups	28034
that in the sham groups -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- A -RRB- and 5 -LRB- C -RRB- -RRB-	28100
that	28100
the sham groups -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- A -RRB- and 5 -LRB- C -RRB- -RRB-	28108
the sham groups -LRB- < 0.05 -RRB-	28108
the sham groups	28108
< 0.05	28128
<	28128
0.05	28130
Figures 5 -LRB- A -RRB- and 5 -LRB- C -RRB-	28137
Figures	28137
5 -LRB- A -RRB- and 5 -LRB- C -RRB-	28145
5 -LRB- A -RRB-	28145
5 -LRB- C -RRB-	28154
We	28161
the spinal cord cell apoptosis rate in cotransplant treated group	28180
the spinal cord cell apoptosis rate	28180
cotransplant treated group	28219
that in the OECs treated and BMSCs treated groups 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB- -RRB-	28261
that in the OECs treated	28261
that	28261
the OECs treated	28269
the OECs	28269
BMSCs treated groups 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB- -RRB-	28290
BMSCs	28290
groups	28304
28 days	28311
transplantation	28325
< 0.05	28345
<	28345
0.05	28347
Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB-	28354
Figures	28354
5 -LRB- B -RRB- and 5 -LRB- C -RRB-	28362
5 -LRB- B -RRB-	28362
5 -LRB- C -RRB-	28371
The spinal cord cell apoptosis rate in the shamgroups , theOECs treated group , BMSCs treated group , and cotransplant treated group	28378
The spinal cord cell apoptosis rate in the shamgroups , theOECs treated group	28378
The spinal cord cell apoptosis rate	28378
the shamgroups , theOECs treated group	28417
the shamgroups	28417
theOECs treated group	28433
theOECs	28433
group	28449
BMSCs treated group	28456
BMSCs	28456
group	28470
cotransplant treated group	28481
the higher spinal cord cell apoptosis rate	28526
the higher spinal cord cell	28526
apoptosis rate	28554
sham groups	28585
the control group , the OECs treated group , BMSCs treated group , and cotransplant treated group 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB- -RRB-	28611
the control group	28611
the OECs treated group , BMSCs treated group , and cotransplant treated group 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB- -RRB-	28630
the OECs treated group	28630
the OECs	28630
group	28647
BMSCs treated group	28654
BMSCs	28654
group	28668
cotransplant treated group 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB- -RRB-	28679
cotransplant treated group	28679
28 days	28706
transplantation -LRB- < 0.05 -RRB- -LRB- Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB- -RRB-	28720
transplantation -LRB- < 0.05 -RRB-	28720
transplantation	28720
< 0.05	28740
<	28740
0.05	28742
Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB-	28749
Figures	28749
5 -LRB- B -RRB- and 5 -LRB- C -RRB-	28757
5 -LRB- B -RRB-	28757
5 -LRB- C -RRB-	28766
these results	28782
we	28797
the cotransplantation of OECs with BMSCs	28819
the cotransplantation	28819
OECs with BMSCs	28844
OECs	28844
BMSCs	28854
antiapoptotic effects in adult rats	28867
antiapoptotic effects	28867
adult rats	28892
SCI	28909
3.6	28914
Expressions of Bax , Bcl-2 , Caspase-9 , and Caspase-3 in Spinal Cord of Rats	28919
Expressions	28919
Bax , Bcl-2 , Caspase-9 , and Caspase-3 in Spinal Cord of Rats	28934
Bax , Bcl-2 , Caspase-9 , and Caspase-3	28934
Spinal Cord of Rats	28974
Spinal Cord	28974
Rats	28989
Olfactory Ensheathing Cells with Bone Marrow Mesenchymal Stem Cells 14 and 28 Days after Transplantation	29012
Olfactory Ensheathing Cells with Bone Marrow	29012
Olfactory Ensheathing Cells	29012
Bone Marrow	29045
Mesenchymal Stem Cells 14	29057
Mesenchymal Stem Cells	29057
14	29080
28 Days after Transplantation	29087
28 Days	29087
Transplantation	29101
Figure 6	29118
the expressions of Caspase-9 and Caspase-3 proteins	29139
the expressions	29139
Caspase-9 and Caspase-3 proteins	29158
Bcl-2 proteins	29226
< 0.05	29278
<	29278
0.05	29280
Figures 6 -LRB- c -RRB- , 6 -LRB- d -RRB- , and 6 -LRB- e -RRB-	29287
Figures	29287
6 -LRB- c -RRB- , 6 -LRB- d -RRB- , and 6 -LRB- e -RRB-	29295
6 -LRB- c -RRB-	29295
6	29295
c	29297
6 -LRB- d -RRB-	29301
6	29301
d	29303
6 -LRB- e -RRB-	29311
6	29311
e	29313
14 and 28 days after transplantation , the levels of Caspase-9 and Caspase-3 proteins	29318
14 and 28 days	29318
transplantation , the levels of Caspase-9 and Caspase-3 proteins	29339
transplantation	29339
the levels of Caspase-9 and Caspase-3 proteins	29356
the levels	29356
Caspase-9 and Caspase-3 proteins	29370
Bcl-2 protein	29431
the OECs treated groups , BMSCs treated groups , and cotransplant treated groups -LRB- < 0.05 -RRB- -LRB- Figures 6 -LRB- c -RRB- , 6 -LRB- d -RRB- , and 6 -LRB- e -RRB- -RRB-	29472
the OECs treated groups	29472
the OECs	29472
groups	29489
BMSCs treated groups	29497
BMSCs	29497
groups	29511
cotransplant treated groups -LRB- < 0.05 -RRB- -LRB- Figures 6 -LRB- c -RRB- , 6 -LRB- d -RRB- , and 6 -LRB- e -RRB- -RRB-	29523
cotransplant treated groups -LRB- < 0.05 -RRB-	29523
cotransplant treated groups	29523
< 0.05	29555
<	29555
0.05	29557
Figures 6 -LRB- c -RRB- , 6 -LRB- d -RRB- , and 6 -LRB- e -RRB-	29564
Figures	29564
6 -LRB- c -RRB- , 6 -LRB- d -RRB- , and 6 -LRB- e -RRB-	29572
6 -LRB- c -RRB-	29572
6	29572
c	29574
6 -LRB- d -RRB-	29578
6	29578
d	29580
6 -LRB- e -RRB-	29588
6	29588
e	29590
The expressions of Caspase-9 and Caspase-3	29595
The expressions	29595
Caspase-9 and Caspase-3	29614
cotransplant	29651
treated groups	29664
those in OECs treated groups and BMSCs treated groups 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 6 -LRB- d -RRB- and 6 -LRB- e -RRB- -RRB-	29709
those	29709
OECs treated groups and BMSCs treated groups 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 6 -LRB- d -RRB- and 6 -LRB- e -RRB- -RRB-	29718
OECs	29718
groups and BMSCs treated groups 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Figures 6 -LRB- d -RRB- and 6 -LRB- e -RRB- -RRB-	29731
groups and BMSCs	29731
groups	29756
28 days	29763
transplantation	29777
< 0.05	29797
<	29797
0.05	29799
Figures 6 -LRB- d -RRB- and 6 -LRB- e -RRB-	29806
Figures	29806
6 -LRB- d -RRB- and 6 -LRB- e -RRB-	29814
6 -LRB- d -RRB-	29814
6 -LRB- e -RRB-	29823
Caspase-9 and Caspase-3	29841
cotransplant treated groups	29878
no significant difference when compared with control groups 28 days after transplantation -LRB- > 0.05 -RRB- -LRB- Figures 6 -LRB- d -RRB- and 6 -LRB- e -RRB- -RRB-	29912
no significant difference	29912
control groups	29957
28 days	29972
transplantation	29986
> 0.05	30006
>	30006
0.05	30008
Figures 6 -LRB- d -RRB- and 6 -LRB- e -RRB-	30015
Figures	30015
6 -LRB- d -RRB- and 6 -LRB- e -RRB-	30023
6 -LRB- d -RRB-	30023
6 -LRB- e -RRB-	30032
There	30039
higher expression of Bcl-2 protein in cotransplant treated groups	30049
higher expression	30049
Bcl-2 protein in cotransplant treated groups	30070
Bcl-2 protein	30070
cotransplant treated groups	30087
28 days	30115
transplantation -LRB- < 0.05 -RRB-	30129
transplantation	30129
< 0.05	30149
<	30149
0.05	30151
c	30167
Bax	30180
little change in each group -LRB- Figure 6 -LRB- b -RRB- -RRB-	30188
little change	30188
each group -LRB- Figure 6 -LRB- b -RRB- -RRB-	30205
each group	30205
Figure 6 -LRB- b -RRB-	30217
Figure	30217
6 -LRB- b -RRB-	30224
3.7	30231
Recovery of Locomotor Function of Rats Cotransplanted with Olfactory Ensheathing Cells with Bone Marrow Mesenchymal Stem Cells .	30236
Recovery	30236
Locomotor Function	30248
Rats Cotransplanted with Olfactory Ensheathing Cells	30270
Rats Cotransplanted	30270
Olfactory Ensheathing Cells	30295
Bone Marrow Mesenchymal Stem Cells	30328
we	30373
inhibition of apoptotic by OECs and MSCs	30391
inhibition	30391
apoptotic by OECs and MSCs	30405
apoptotic	30405
OECs and MSCs	30418
the functional recovery of rats	30455
the functional recovery	30455
rats	30482
BBB scores at all time points after transplantation for the cotransplant treated , OECs treated , and BMSCs treated groups and control groups	30488
BBB scores	30488
all time points after transplantation for the cotransplant treated , OECs treated , and BMSCs treated groups and control groups	30502
all time points	30502
transplantation for the cotransplant treated , OECs treated , and BMSCs treated groups and control groups	30524
transplantation for the cotransplant treated	30524
transplantation	30524
the cotransplant treated	30544
the cotransplant	30544
OECs treated	30570
OECs	30570
BMSCs treated groups and control groups	30588
BMSCs	30588
groups and control groups	30602
Tables 2 and 3 , which showed that the mean BBB score decreased significantly in the treatment groups compared to that in control groups before transplantation -LRB- < 0.05 -RRB-	30641
Tables 2 and 3	30641
the mean BBB score	30675
the treatment groups	30721
that in control groups before transplantation -LRB- < 0.05 -RRB-	30754
that	30754
control groups before transplantation -LRB- < 0.05 -RRB-	30762
control groups	30762
transplantation -LRB- < 0.05 -RRB-	30784
transplantation	30784
< 0.05	30804
<	30804
0.05	30806
Recovery of function	30813
Recovery	30813
function	30825
the course of the 14-day observation period in the OECs treated group , BMSCs treated group , and cotransplant treated group	30868
the course	30868
the 14-day observation period in the OECs treated group , BMSCs treated group , and cotransplant treated group	30882
the 14-day observation period in the OECs treated group	30882
the 14-day observation period	30882
the OECs treated group	30915
the OECs	30915
group	30932
BMSCs treated group	30939
BMSCs	30939
group	30953
cotransplant treated group	30964
Rats in the transplanted groups	30992
Rats	30992
the transplanted groups	31000
a significant improvement in the BBB scale relative to the sham injured control group 14 , 21 , and 28 days	31031
a significant improvement	31031
the BBB scale	31060
the sham injured control group	31086
14 , 21 , and 28 days	31117
14 , 21 , and 28	31117
days	31132
transplantation -LRB- < 0.05 -RRB- -LRB- Table 3 -RRB-	31143
transplantation -LRB- < 0.05 -RRB-	31143
transplantation	31143
< 0.05	31163
<	31163
0.05	31165
Table 3	31172
The BBB scale in cotransplant treated group	31182
The BBB scale	31182
cotransplant treated group	31199
that in OECs treated group and BMSCs treated group 21 and 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Table 3 -RRB-	31262
that	31262
OECs treated group and BMSCs treated group 21 and 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Table 3 -RRB-	31270
OECs	31270
group and BMSCs treated group 21 and 28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Table 3 -RRB-	31283
group and BMSCs	31283
group 21 and 28 days	31307
group 21	31307
28 days	31320
transplantation -LRB- < 0.05 -RRB- -LRB- Table 3 -RRB-	31334
transplantation -LRB- < 0.05 -RRB-	31334
transplantation	31334
< 0.05	31354
<	31354
0.05	31356
Table 3	31363
Discussion Transplantation of OECs and BMSCs	31377
Discussion Transplantation	31377
OECs and BMSCs	31407
therapy of SCI -LSB- 27 -- 30	31482
therapy	31482
SCI -LSB- 27 -- 30	31493
clinical application	31516
the margin neuronal differentiation capacity of BMSC as well as the limited number of isolatableOECs	31559
the margin neuronal differentiation capacity of BMSC	31559
the margin neuronal differentiation capacity	31559
BMSC	31607
the limited number of isolatableOECs	31623
the limited number	31623
isolatableOECs	31645
advantage	31669
the limitations	31691
ofOECs and BMSCs	31707
the cotransplantation of the two major types of cells	31725
the cotransplantation	31725
the two major types of cells	31750
the two major types	31750
cells	31773
therapeutic for SCI	31801
therapeutic	31801
SCI	31817
this study	31825
we successfully coculture the two types of cells in vitro	31837
we successfully coculture the two types	31837
we	31837
coculture the two types	31853
coculture	31853
the two types	31863
cells in vitro	31880
cells	31880
There	31896
no morphological change in cell.We	31906
no morphological change	31906
cell.We	31933
the cells immunofluorescence	31950
the viability of the individual	31992
the viability	31992
the individual	32009
cells	32039
BMSCs	32046
rapid proliferation	32059
more pronounced increase	32084
the number of cells	32112
the number	32112
cells	32126
the OECs	32139
low growth rate	32153
nonsignificant increase in cell number during the culture period.There	32175
nonsignificant increase	32175
cell number during the culture period.There	32202
cell number	32202
the culture period.There	32221
a need to ensure that the number of each cell to avoid the imbalance in the proportion of cells in the coculture system	32249
the number of each cell	32271
the number	32271
each cell	32285
the imbalance	32304
the proportion of cells in the coculture system	32321
the proportion	32321
cells in the coculture system	32339
cells	32339
the coculture system	32348
Consistent with several previous studies -LSB- 31 -- 33 -RSB- , in this study we demonstrated that transplantation of either of OECs or BMSCs alone is able to promote functional recovery of rats after SCI .	32370
Consistent with several previous studies -LSB- 31	32370
Consistent	32370
several previous studies -LSB- 31	32386
several previous studies	32386
31	32412
33 -RSB- , in this study we demonstrated that transplantation of either of OECs or BMSCs alone is able to promote functional recovery of rats after SCI	32415
33 -RSB-	32415
this study we demonstrated that transplantation of either of OECs or BMSCs alone is able to promote functional recovery of rats after SCI	32423
this study	32423
we	32434
transplantation of either of OECs or BMSCs	32455
transplantation	32455
either of OECs or BMSCs	32474
either	32474
OECs or BMSCs	32484
functional recovery of rats	32523
functional recovery	32523
rats	32546
SCI	32557
the cotransplantation of OECs and BMSCs	32577
the cotransplantation	32577
OECs and BMSCs	32602
the most effective in comparison with that of OECs or BMSCs	32638
the most effective	32638
comparison with that of OECs or BMSCs	32660
comparison	32660
that of OECs or BMSCs	32676
that	32676
OECs or BMSCs	32684
the two cell typesmay	32725
a synergistic way	32759
the functional recovery of SCI	32788
the functional recovery	32788
SCI	32815
Deng et al. -LSB- 34 -RSB-	32820
Deng et al. -LSB-	32820
the cotransplant group	32855
significantly better improvement of gait scaling compared with all other groups	32896
significantly better improvement	32896
gait scaling compared with all other groups	32932
gait scaling	32932
all other groups	32959
2 weeks of transplantation.TheBMSC group	32982
2 weeks	32982
transplantation.TheBMSC group	32993
higher BBB scores	33041
the OEC group , which is consistent with our findings	33064
the OEC group	33064
our findings	33104
the cotransplant of OECs and BMSCs	33131
the cotransplant	33131
OECs and BMSCs	33151
effective change	33178
that of OECs and BMSCs	33209
that	33209
OECs and BMSCs	33217
this regard	33242
the cograft of mixed cell types with complementary properties	33255
the cograft	33255
mixed cell types with complementary properties	33270
mixed cell types	33270
complementary properties	33292
a novel approach for cell transplantation	33329
a novel approach	33329
cell transplantation	33350
SCI and even other tissue types	33374
SCI	33374
other tissue types	33387
much attention	33416
secondary cord injury	33448
this	33476
therapeutic intervention	33511
Apoptosis and inflammatory responses and some other neurological toxicity events	33537
Apoptosis and inflammatory responses	33537
some other neurological toxicity events	33578
the secondary injury	33630
primary insult inthe spinal cord -LSB- 1 , 35 -RSB-	33657
primary insult inthe	33657
-LSB- 1 , 35	33690
this study	33710
the possible synergistic effects of the two cells	33739
the possible synergistic effects	33739
the two cells	33775
antiapoptotic effects	33793
cotransplantation in rat SCI models	33821
cotransplantation	33821
rat SCI models	33842
We	33858
decreased apoptosis in rats	33867
decreased apoptosis	33867
rats	33890
group of cotransplantation of OECs and BMSCs	33900
group	33900
cotransplantation of OECs and BMSCs	33909
cotransplantation	33909
OECs and BMSCs	33930
apoptosis study using TUNEL assay which showed	33950
apoptosis study	33950
TUNEL assay which showed	33972
TUNEL assay	33972
The spinal cord cell apoptosis rate in the OECs treated , BMSCs treated , and cotransplant treated groups	33998
The spinal cord cell apoptosis rate in the OECs treated	33998
The spinal cord cell apoptosis rate	33998
the OECs treated	34037
the OECs	34037
BMSCs treated	34055
BMSCs	34055
cotransplant treated groups	34074
that in the sham groups	34140
that	34140
the sham groups	34148
the spinal cord cell apoptosis rate in cotransplant treated group	34178
the spinal cord cell apoptosis rate	34178
cotransplant treated group	34217
that in the OECs treated and BMSCs treated groups 28 days after transplantation	34259
that in the OECs treated	34259
that	34259
the OECs treated	34267
the OECs	34267
BMSCs treated groups 28 days after transplantation	34288
BMSCs	34288
groups	34302
28 days	34309
transplantation	34323
we	34355
death of injured spinal cord cells in whitematter following spinal cord injury	34374
death	34374
injured spinal cord cells in whitematter following spinal cord injury	34383
injured spinal cord cells	34383
whitematter following spinal cord injury	34412
whitematter	34412
spinal cord injury	34434
the regulations processing of Bax , Bcl-2 , Caspase-9 , andCaspase - 3	34462
the regulations processing of Bax , Bcl-2 , Caspase-9 , andCaspase	34462
the regulations processing	34462
Bax , Bcl-2 , Caspase-9 , andCaspase	34492
3	34527
the apoptotic death of cells in the spinal cord	34560
the apoptotic death	34560
cells in the spinal cord	34583
cells	34583
the spinal cord	34592
Increased activity of theCaspase family of proteases	34609
Increased activity	34609
theCaspase family of proteases	34631
theCaspase family	34631
proteases	34652
apoptosis during which Caspase - 3 plays a crucial role in SCI-mediated apoptotic cell death in the white matter -LSB- 14 , 36 -RSB-	34681
apoptosis	34681
Caspase	34704
3	34713
a crucial role in SCI-mediated apoptotic cell death in the white matter -LSB- 14 , 36	34721
a crucial role	34721
SCI-mediated apoptotic cell death in the white matter -LSB- 14 , 36	34739
SCI-mediated apoptotic cell death	34739
the white matter	34776
-LSB- 14 , 36	34793
mechanisms underlying suppression	34818
apoptosis	34855
cotransplantation of OECs and BMSCs	34871
cotransplantation	34871
OECs and BMSCs	34892
SCI	34913
we	34918
the Bax , Bcl-2 , Caspase-9 , and Caspase - 3 expression in apoptosis	34935
the Bax , Bcl-2 , Caspase-9 , and Caspase	34935
3 expression in apoptosis	34975
3 expression	34975
apoptosis	34991
Western blot	35004
The results	35018
the expression of Caspase-9 and Caspase - 3 and the ratio of Bax/Bcl -2	35048
the expression of Caspase-9 and Caspase - 3 and the ratio	35048
the expression of Caspase-9 and Caspase	35048
the expression	35048
Caspase-9 and Caspase	35066
3 and the ratio	35089
3	35089
the ratio	35095
Bax/Bcl -2	35108
the cotransplant treated group compared with those in the sham groups	35150
the cotransplant	35150
group	35175
those in the sham groups	35195
those	35195
the sham groups	35204
the expression of Bax	35230
the expression	35230
Bax	35248
little change in each group	35256
little change	35256
each group	35273
we	35296
downregulation of Bcl-2 and consequently the higher ratio of Bax/Bcl -2	35315
downregulation of Bcl-2	35315
downregulation	35315
Bcl-2	35333
the higher ratio of Bax/Bcl -2	35356
the higher ratio	35356
Bax/Bcl -2	35376
the release of Caspase-9 and Caspase-3	35418
the release	35418
Caspase-9 and Caspase-3	35433
the latter	35467
apoptosis	35498
SCI	35514
The cotransplantation of OECs with BMSCs	35519
The cotransplantation	35519
OECs with BMSCs	35544
OECs	35544
BMSCs	35554
antiapoptotic effects in adult rats	35567
antiapoptotic effects	35567
adult rats	35592
spinal cord injury by inhibiting downregulation of Bcl-2 expression	35609
spinal cord injury	35609
inhibiting downregulation of Bcl-2 expression	35631
inhibiting downregulation	35631
Bcl-2 expression	35660
the decrease in the ratio of Bax/Bcl -2 results in the suppression of Caspase-9 and Caspase-3 , leading to a decrease in the number of apoptotic cells in the cotransplant	35692
the decrease	35692
the ratio of Bax/Bcl -2 results in the suppression of Caspase-9 and Caspase-3 , leading to a decrease in the number of apoptotic cells in the cotransplant	35708
the ratio	35708
Bax/Bcl -2 results	35721
the suppression of Caspase-9 and Caspase-3	35742
the suppression	35742
Caspase-9 and Caspase-3	35761
a decrease in the number of apoptotic cells	35797
a decrease	35797
the number of apoptotic cells	35811
the number	35811
apoptotic cells	35825
the cotransplant	35844
group	35869
These findings	35876
OECs and BMSCs	35914
the neuroprotective effects	35944
apoptotic processes	35985
the expression of the mitochondria-associated intrinsic pathway related proteins	36019
the expression	36019
the mitochondria-associated intrinsic pathway related proteins	36037
secondary damage of SCI	36107
secondary damage	36107
SCI	36127
this study	36135
we	36147
transplantation of OECs , BMSCs , and cotransplantation of OECs with BMSCs	36161
transplantation	36161
OECs , BMSCs , and cotransplantation	36180
OECs with BMSCs	36218
OECs	36218
BMSCs	36228
functional activities of rats	36260
functional activities	36260
rats	36285
two weeks of transplantation	36296
two weeks	36296
transplantation	36309
we	36339
there	36353
significant functional recovery , improvement in the number of intact axons across the injury site , and a decrease in white matter loss in cotransplant treated group compared to that in OECs treated group and BMSCs treated group 21 and 28 days after transplantation	36363
significant functional recovery	36363
improvement in the number of intact axons across the injury site	36396
improvement	36396
the number of intact axons across the injury site	36411
the number	36411
intact axons across the injury site	36425
intact axons	36425
the injury site	36445
a decrease in white matter loss in cotransplant treated group compared to that in OECs treated group and BMSCs treated group 21 and 28 days after transplantation	36466
a decrease	36466
white matter loss in cotransplant treated group compared to that in OECs treated group and BMSCs treated group 21 and 28 days after transplantation	36480
white matter loss	36480
cotransplant treated group compared to that in OECs treated group and BMSCs treated group 21 and 28 days after transplantation	36501
cotransplant treated group	36501
that in OECs treated group and BMSCs treated group 21 and 28 days after transplantation	36540
that	36540
OECs treated group and BMSCs treated group 21 and 28 days after transplantation	36548
OECs	36548
group and BMSCs treated group 21 and 28 days after transplantation	36561
group and BMSCs	36561
group 21 and 28 days	36585
group 21	36585
28 days	36598
transplantation	36612
The finding of the locomotor recovery in treated rats	36629
The finding	36629
the locomotor recovery in treated rats	36644
the locomotor recovery	36644
treated rats	36670
the mitochondriaassociated intrinsic pathway	36697
a potential therapeutic target in the treatment of SCI	36751
a potential therapeutic target	36751
the treatment of SCI	36785
the treatment	36785
SCI	36802
Our study	36807
the previous studies -LSB- 37 -- 41 -RSB- indicating that stem cells could migrate and accumulate in the injured areas , differentiate into neural cells , and improve the functional recovery of these animals	36835
the previous studies	36835
37 -- 41 -RSB- indicating that stem cells could migrate and accumulate in the injured areas , differentiate into neural cells , and improve the functional recovery of these animals	36857
37 -- 41	36857
stem cells	36880
the injured areas	36923
neural cells	36961
the functional recovery of these animals	36987
the functional recovery	36987
these animals	37014
